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Background and Purpose: Colorectal cancer (CRe) is an insidious cancer associated with
significant morbidity and mortality. In Canada, it is the second leading cause of cancer
death. Newfoundland and Labrador has the highest rate of CRC of all ten Canadian
provinces and is ideal for examining founder effects and studying incidence of hereditary
disease in what is essentially a closed community. Family history is the strongest risk
factor for this disease. Inherited deleterious variants in the mismatch repair (MMR)
genes playa critical role in the development of some cases, but families exist who have a
family history consistent with autosomal dominant inheritance and no known
predisposing genes (Familial colorectal cancer type X, FCCTX). The aim of this study is
to determine the genetic basis ofCRC in Newfoundland and Labrador, defined by family
history, molecular pathology of the CRC and molecular genetics, in an incident cohort of
CRC cases occurring in the population during one year.
Methods: A study population of 262 consecutively diagnosed CRC cases from the
Newfoundland population were identified and following application of the recruitment
protocol 148 participants, 144 families, completed the study. Eligible probands were
contacted for consent and with this permission tumour blocks were obtained. Detailed
family histories were obtained and risk classified. Tests of microsatellite stability and
immunohistochemistry for mismatch repair proteins in tumour blocks were performed.
Cancer phenotypes in family members of patients with CRC were compared in various
high risk groups.
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Results: 12.5% offamilies (n=18) were classified as high risk according to Amsterdam
criteria (AC) and Age and Cancer modified Amsterdam criteria (ACMAC). An
additional 33.3% fulfilled the revised Bethesda guidelines for intermediate risk
classification and 53.5% were low risk. Fifteen (10.9%) families demonstrated
rnicrosatellite instability with thirteen (86.7%) of these having a corresponding deficiency
in mismatch repair proteins. Eleven of the fifteen high risk families (61.1 %) were
microsatellite stable (MSS) and had no mismatch repair protein deficiency and family
history was consistent with FCCTX or age modified FCCTX. FCCTX family members
had a lower frequency of both CRC and Lynch syndrome associated cancers as well as a
later age of cancer onset compared to possible Lynch syndrome.
Conclusions: The incidence ofCRC with high or intermediate risk family history is high
in Newfoundland and Labrador. Families with a history consistent with autosomal
dominant disease occurred in 12.5%; possible Lynch syndrome was suspected in a
minority (35%) of these families, and FCCTX/age modified FCCTX in the majority.
Phenotype differences exist between FCCTX and suspected LS families in both age of
onset and cancer frequency among relatives. Opportunity for novel gene discovery exists
because the molecular genetic basis for most of those with familial CRC was not
determined.
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Notes to the Reader
I. I started this thesis in 2002 after working as a research assistant with the Clinical
Epidemiology Department. After completing the course work required for the masters
program, I was accepted into medical school. Data collection and analysis were
completed during medical school but due to the time restraints of being a medical
resident, as well as being away in Kingston, Ontario, I was not able to dedicate the
time which was required to complete my thesis. Upon conclusion of my residency and
having moved back home to start a career in family medicine, I decided the
completion of my Masters of Science was very important to me both personally and
professionally. With the support of my supervisory committee and despite working
full time I completed my thesis as it had been originally designed. Unfortunately,
however, the results of this study could no longer be released as a preliminary analysis
of a portion of the larger collaborative project as had been intended. The five year
study had been completed and the results published. The detailed mutational analysis
published by Woods et al.(20 10) was never intended to be incorporated into this study
as it was to be an extension of and more inclusive than these results. It was completed
by a separate team of researchers than those whom I received the molecular data
results. All of my data had been compiled and analyzed prior to the release of this
study but where possible I have made reference to corresponding results published by
Woods et al. (2010). Significant advancements have been made in the research of
Lynch syndrome since the collection of this data and I have attempted to present my
data in light of these. While mutation analysis is the gold standard in diagnosis ofLS,
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it is also very expensive. With a more detailed analysis of family history risk
classification along with the more economical molecular analyses, the clinical
relevance of the information presented in this thesis should not be underestimated.
2. This project involves the incident CRC cases in the first year of data collected for a
CIHR funded 5 year study. My two year involvement with this project initially began
as a research assistant and then as a masters student. My main research role included
helping with recruitment ofparticipants, collection of the family history data and risk
classification offamilies recruited for the entire project. For the population subset
included in this thesis, I was totally responsible for the family history risk
classification as well as the analysis of the molecular information in combination with
family history data. Details of the work performed as well as identifying that
contributed by other team members can be found throughout the methods section.
3. Since the start of my work, the terminology related to familial CRC has evolved.
Most in the field now use the term Lynch syndrome (LS) as the preferred synonym
over Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and is used as such
throughout the thesis. Specifically, LS is the genetic definition indicating a patient has
an inherited pathogenic variant in an MMR gene while HNPCC is the clinical
definition based on one's family history.
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4. The molecular component of this research was completed and provided by Dr. Roger
Green and the molecular lab teams. Without their work this thesis would not have
been possible.
---------l( v )1---------
Acknowledgments
I would like to thank my supervisor Dr. Patrick Parfrey and supervisory committee for
providing me the opportunity to complete this project as well as for their support despite
the interruption of medical school and residency training; Dr. Roger Green and the
molecular lab teams for providing me with the molecular results; Dr. Jane Green for her
expertise in pedigree analysis and family history classification; Dr. Elizabeth Dicks and
the recruitment team for their continued support and participant information; My family
and friends for their encouragement over these last 9 years. Finally, I would like to thank
my husband Stephen Crane who brought me back home and stood by me throughout this
long process.
------~(Vi
Chapter I Introduction .
Table of Contents
. 1
Colorectal Cancer .....1.1
1.1.1 Definition .
.••••.••• 1
......• 1
1.1.2 HNPCC to Lynch Syndrome 2
1.1.3 FAP 2
1.1.4 MAP 3
1.2 Nomenclature of Hereditary Colon Cancer. 3
1.2.1 Amsterdam Criteria I 3
1.2.2 Amsterdam Criteria II .4
1.2.3 Molecular Characterization .5
1.2.4 Bethesda Guidelines 6
1.2.5 Lynch Syndrome 8
1.2.6 Familial Colorectal Cancer Type X 9
1.2.7 Common Familial Risk Colon Cancer 10
1.3 Clinical Features 10
1.4 Colorectal Cancer and Family History 11
1.5 MicrosatelliteInstability........................ . 12
1.6 DNA MMR System 14
1.6.1 MLH 1 Promoter Methylation.. . 15
1.7 Correlation between MSI and MMR 17
1.8 Family History and Molecular Testing 17
1.9 Incidence 19
1.10 Genotype-Phenotype Variation
1.11 Newfoundland Population .
................................................21
. 23
----~( vii )1------
1.12 Rationale..... . 24
1.13 Background .. 25
1.13.1 CRC-IHRT Results.. .. 27
1.14 Objectives . . 28
Chapter 2 Material and Methods .. 29
2.1 Study Population Selection 29
2.1.1 Inclusion Criteria 30
2.1.2 Exclusion Criteria .30
2.1.3 Proxy Identification 30
2.1.4 Recruitrnent. 3I
2.2 Data Collection 33
2.2.1 Family History Questionnaire 34
2.2.2 Verification of Cancers 34
2.2.3 Health Regions 35
2.3 Family History Risk Assignment... .37
2.3.1 High Risk 37
2.3.2 Intermediate Risk 38
2.3.3 Low Risk (Sporadic).......................... .. 38
2.4 Genetic Counselling...... .. ...39
2.5 Tumour Blocks 39
2.6 Molecular Analysis...... . .40
2.6.1 Microsatellite Instability .40
2.6.2 Immunohistochemistry Staining 40
2.7 Genetic Classification....... . .41
2.8 Analysis . ................................................................ .41
2.9 Ethical Considerations. . .. .. .42
-------f( viii )1-----
Chapter 3 Results ............... .44
3.1 Characteristics of Participants... . . .... .44
3.2 Family History Study............................... . .46
3.2.1 Risk Classification .46
3.2.2 Low Risk Family Informativeness .50
3.2.3 Distribution of Family Risk According to Provincial Regions 50
3.2.4 Summary of Family History Reported Cancers 53
3.2.5 Confirmation of Family Reported Cancers .58
3.3 Molecular Laboratory Study 62
3.3.1 Tumour Collection 62
3.3.2 Microsatellite Analysis 62
3.3.3 Immunohistochemistry Results 62
3.4 Family History Risk Classification and Molecular Study Correlation 66
3.4.1 High Risk Families 66
3.4.2 Intermediate Risk Families 69
3.4.3 Low Risk Families 72
3.5 Phenotype Considerations 74
3.5.1 Colorectal Cancer. 74
3.5.2 Extra-Colonic Cancers 74
Chapter 4 Discussion and Conclusion 80
References 92
--------f( ix )1-------
Table A: Loss of Immunohistochemistry Staining in Relation to Affected Mismatch Repair
Gene.... . 15
Table I: Characteristics of Participants (n=148) and Non-Participants (n=82) .45
Table 2: Frequencies of Family History Classifications Organized by Risk
Category .47
Table 3: Final Family History Classification Frequencies... . .49
Table 4: Incidence Rates of Colon Cancer in 1999 According to Provincial Region for ages
20-74 51
Table 4A: Comparison of Frequencies of Family History Risk Classifications Between
Provincial Health Regions... .. .52
Table 5: Frequency ofFamily History Reported Cancers for Amsterdam Criteria I Families
According to Specific Cancer Type Categories (n = 4) 54
Table 6: Frequency of Family History Reported Cancers for Age and Cancer Modified
Amsterdam Criteria Families According to Specific Cancer Type Categories (n = 14) ......55
Table 7: Frequency of Family History Reported Cancers for Intermediate Risk Families
According to Specific Cancer Type Categories (n = 48) 56
Table 8: Frequency of Family History Reported Cancers for Low Risk Families According to
Specific Cancer Type Categories (n = 77) 57
Table 9: Summary of Cancer Confirmation for Family History Reported Cancers for First
and Second Degree Relatives 60
Table 10: Summary of Cancer Confirmation for Family History Reported Cancers for First
and Second Degree Relatives According to Family History Risk Classification 61
Table II: Summary of Microsatellite Analysis Results for All Tumours Collected 64
Table 12: Summary of Immunohistochemistry Analysis Results for All Tumours 65
Table 13: Comparison of Age of Onset ofCRC Occurrence between possible LS and FCCTX
Families.... . ...75
Table 14: Comparison of Age of Onset of Extra-Colonic Cancer Occurrence between
possible LS and FCCTX Families.... . 78
-------4( x
Figure I: Summary of Recruitment of Study Participants...... ...32
Figure 2: Six Defined Health Regions ofNewfoundland and Labrador..... .. .......36
Summary of Tumour Collection According to Family History
Figure 4: Summary of Classification of High Risk Families According to Molecular Data
Results 67
Figure 5: Molecular Data Correlation According to Specific High Risk Category.........68
Figure 6: Family History and Molecular Data Correlation ofMSI and mc for
Intermediate Risk Families 70
Figure 7: Molecular Data Correlation ofMSI and IHC for Family History Classified
Intermediate Risk Families According to Individual Revised Bethesda Guidelines.........71
Figure 8: Family History and Molecular Data Correlation ofMSI and mc for Family
History Classified Low Risk Families............................................. . 73
Figure 9: Comparison of Age of Onset of CRC Occurrence between Possible LS and
FCCTX Families 76
Figure 10: Comparison of Age of Onset of Extra-Colonic Cancer Occurrence between
possible LS and FCCTX Families 79
ACMAC Age and Cancer Modified Amsterdam Criteria
AFAP Attenuated Familial Adenomatous Polyposis
AC I Amsterdam Criteria I
ACII Amsterdam Criteria II
APC Adenomatous Polyposis Coli gene
CRC Colorectal Cancer
CRC-IHRT Colorectal Cancer Interdisciplinary Health Research Team
FAP Familial Adenomatous Polyposis
FCCTX Familial Colorectal Cancer Type X
FHQ Family History Questionnaire
HNPCC Hereditary Nonpolyposis Colorectal Cancer
ICG-HNPCC International Collaborative Group on Hereditary Nonpolyposis Colorectal
Cancer
IHC Immunohistochemistry
IR Intermediate Risk
LS Lynch Syndrome
MAP MUTYH-Associated Polyposis
MMR Mismatch Repair
MSI Microsatelliteinstability
MSS MicrosatelliteStable
NL Newfoundland and Labrador
PMGP Provincial Medical Genetics Program
RBG Revised Bethesda Guidelines
ROI Request of Information
---------f( xii )1--------
Chapter 1: Introduction
1.1 Colorectal Cancer
1.1.1 Definition
Colorectal cancer (CRC) is an insidious cancer originating in the colon or rectum.
In Canada, it is the second leading cancer causing death for men and women combined.
An estimated 22,200 Canadians will be diagnosed with colorectal cancer in 2011 with
8,900 dying from their disease. When colorectal cancer is diagnosed in its early stages, it
is curable. This emphasizes the importance and value in effective and appropriate
screening for those at increased risk (Canadian Cancer Society, July 16, 2011).
Colorectal cancer can be broadly classified into two main categories: inherited and
sporadic. Up to thirty percent of CRC has a hereditary component (Lichtenstein et aI.,
2000; Grady, 2003). Mendelian inherited conditions account for 5% of cases and have a
recognized phenotype. The remaining cases with a family history of CRC are less well
defined (Lynch & de la Chapelle, 2003).
Well defined inherited forms of colorectal cancer are based on clinical,
pathological and genetic criteria. The most common hereditary forms include Lynch
syndrome (LS), familial adenomatous polyposis (FAP), and MUTYH-Associated
polyposis (MAP).
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1.1.2 HNPCC to Lynch Syndrome
Throughout the decades many names have been used to classify this most
common hereditary form of CRC. Initially, it was called family cancer syndrome which,
in the 1980's, was changed to Lynch syndrome I and Lynch syndrome II, differentiating
those that had primarily colorectal cancer from those who also had uterine and other
extra-colonic cancers (Boland & Truncale, 1984). In order to distinguish this syndrome
from FAP the term hereditary nonpolyposis hereditary colon cancer (HNPCC) was coined
(Lynch et aI., 1985). HNPCC has no pathognomonic feature and cancer is frequently
found at extra-colonic sites. Multiple classification systems including Amsterdam criteria
I (ACI), Amsterdam criteria II (ACII) and Bethesda guidelines have been developed and
used in clinical practice to identify individuals at risk for HNPCC who require further
evaluation. However, since the molecular elucidation of the cause ofHNPCC and the
role of mismatch repair (MMR) genes, it has been proposed that families having a known
genetic variant in a MMR gene be referred to as LS while those with no molecular
diagnosis yet fulfilling the ACI be referred to as Familial Colorectal Cancer-type X
(FCCTX) (Lindor et aI., 2005; Boland, 2005).
1.1.3 FAP
This syndrome is the second most common inherited form ofCRC with a
prevalence of I in 10,000. Its characteristic feature is the presence of hundreds to
thousands of colonic polyps. This clinical phenotype allows for an easier diagnosis of
this hereditary disorder. An attenuated form (AFAP) has also been described which has a
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variable number of polyps and reduced penetrance. Both syndromes are attributed to
deleterious germline variations of the adenomatous polyposis coli (APe) gene (Lynch &
de la Chapelle, 2003).
1.1.4 MAP
MAP is characterized by polyposis of the colorectum as well as an increased risk
ofCRC. It is an autosomal recessive inherited syndrome which means siblings of an
affected patient have a 25% chance of being affected and 75% chance of being a carrier
of the associated variant. It is caused by biallelic mutations in MUTYH and genetic
testing for MAP should be considered in those with greater than 10 colorectal adenomas
but do not have an identifiable mutation in APe (Jasperson et aI., 20 I0).
1.2 Nomenclature ofHereditary Colon Cancer
Hereditary colon cancer can be difficult to recognize and diagnose without
established clinical criteria. In addition, as research continues, a framework of
classification is imperative to appropriately compare results and make scientific advances.
As already indicated, HNPCC was the initial nomenclature indicating high familial risk
prior to molecular and genetic advancements leading to the classifications of LS and
FCCTX.
1.2.1 Amsterdam Criteria I
In 1990, to help provide uniformity for collaborative studies, the International
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Collaborative Group on HNPCC (ICG-HNPCC) established a set of criteria to define LS
families:
There should be at least 3 relatives with CRC and all the following criteria should
be present:
• One should be a first degree relative of the other 2
• At least 2 successive generations should be affected
• At least I CRC should be diagnosed before age 50
• Familial adenomatous polyposis should be excluded
• Tumours should be verified by pathological examination
(Vasen, 1991)
Although these criteria provided uniformity for collaborative studies they were
very restrictive. Researchers believed many families would be excluded as extra-colonic
cancers known to be part of the syndrome were not included. Consequently, families at
risk would not receive appropriate hereditary designation and clinically would not avail of
necessary screening and follow up (Vasen, 1999).
1.2.2 Amsterdam Criteria II
Established in 1997, this second set of criteria emerged aiming to provide simple,
clinical criteria that had a high likelihood of identifying LS families. The goal was to
enable a clinical diagnosis without molecular confirmation as not all families would have
access to genetic analyses. The important feature, excluded in the original criteria, is the
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inclusion of extra-colonic tumours. Studies have found cancer of the endometrium,
stomach, ovaries, renal pelvis, brain, and hepatobiliary tract are the most highly
associated with LS. Of these, cancer of the endometrium, ureter, renal pelvis, and small
bowel are considered the most specific and therefore included in the Amsterdam II
criteria (Watson & Lynch, 1993; Vasen et aI., 1996; Sijmons, 1998; Aamio et aI., 1995):
There should be at least 3 relatives with an LS-associated cancer (CRC, cancer of
the endometrium, small bowel, ureter, or renal pelvis):
• One should be a first degree relative of the other 2
• At least 2 successive generations should be affected
• At least I should be diagnosed before age 50
• Familial adenomatous polyposis should be excluded
• Tumours should be verified by pathological examination
1.2.3 Molecular Characterization
The molecular basis ofLS has been established for nearly two decades. A
deleterious variant in a DNA MMR gene (MLH1, MSH2, MSH6, or PMS2) is responsible
for LS. The MMR system maintains genetic stability through correction of single base
pair mismatches and insertion-deletion loops that form during DNA replication. Some
variants in these genes result in an absence of mismatch repair and an accumulation of
errors in stretches of sequences known as microsatellites. Microsatellites are short
segments of DNA that have a repeated sequence and are particularly prone to
insertion/deletion variants. In the absence of repair, the length of the microsatellite is
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altered which is known as microsatellite instability (MSI). Colorectal cancers develop
slowly through the acquisition of these genetic alterations that cannot be corrected by the
repair mechanisms built into each cell. There are only a few common variants but each
tumour has its own genetic alteration making the task of planning treatment very difficult
(Boland & Goel, 2010). Early identification of a hereditary colorectal cancer syndrome
allows appropriate surveillance, and early detection and treatment for family members
leading to reduced morbidity and mortality in carriers (Jarvinen et aI., 2000; Wagner et
aI., 2005). Through molecular advancements, these families can be more accurately
identified through tumor and blood genetic testing.
1.2.4 Bethesda Guidelines
With a better understanding of the clinical and pathological manifestations ofLS a
new set of criteria were developed to identify tumours that should undergo molecular
tumour analyses including microsatellite instability and/or immunohistochemical staining.
If the results of these tests implicated LS, it was recommended to carry out gerrnIine
testing of DNA MMR genes to confirm the diagnosis. In contrast to AC I and II, which
focussed primarily on an extended family history of CRC and LS-associated tumours, the
Bethesda guidelines incorporate young onset and/or multiple primary tumours in patients
whose family history is either incomplete or the pedigree is small, as well as it includes
histopathological presentations. The criteria initially proposed in 1996, and revised in
2002, have been demonstrated to be valuable in selecting families for DNA screening
(Vasen et aI., 2007; Julie et aI., 2008).
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Classical and revised Bethesda guidelines (RBG) include:
Classical Guidelines:
• Individuals with two LS-related cancers, including synchronous and
metachronous colorectal cancers or associated extra-colonic cancers
(endometrial, ovarian, gastric, hepatobiliary, small bowel cancer or transitional
cell carcinoma of the renal pelvis or ureter).
• Individuals with colorectal cancer or endometrial cancer and a first degree
relative with colorectal cancer and/or LS-related extra-colonic cancer and/or
colorectal adenoma; one of the cancers diagnosed at age < 45 years, and the
adenoma diagnosed at age < 40 years.
• Individuals with right-sided colorectal cancer or endometrial cancer diagnosed
atage<45 years.
• Individuals with right-sided colorectal cancer with an undifferentiated pattern
on histopathology diagnosed at age < 45 years.
• Individuals with signet-ring-cell-type colorectal cancer diagnosed at age < 45
years.
• Individuals with adenomas diagnosed at age < 45 years.
Revised Bethesda Guidelines:
• Colorectal cancer diagnosed in a patient < 50 years old.
• Presence of synchronous, metachronous colorectal, or other LS-associated
tumours (colorectal, endometrial, stomach, ovarian, pancreas, ureter, renal
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pelvis, biliary tract, and brain tumours, sebaceous gland adenomas and
keratoacanthomas in Muir Torre syndrome and carcinoma of the small bowel)
regardless of age.
• Colorectal cancer with high microsatellite instability (MSI-H) histology*
diagnosed in a patient < 60 years of age.
• Individual with colorectal cancer and one or more first-degree relatives with a
LS-related tumor, with one of the cancers diagnosed under age of 50 years.
• Individual with colorectal cancer and two or more first-degree or second-
degree relatives with LS-related tumours, regardless of age.
*Presence of tumour infiltrating lymphocytes, Crohn's-like lymphocytic reaction,
mucinous/signet-ring differentiation, or medullary growth pattern
(Vmar et aI., 2004)
1.2.5 Lynch Syndrome
After multiple international conferences and molecular advancements in the study
ofHNPCC, a consensus to more specifically defme the term LS was reached. Familial
colon cancer clustering was to be split between those caused by variants in the APe gene
causing FAP or those caused by failure of the DNA MMR system (Boland, 2005).
Familial clusters whose tumours demonstrate failure of the MMR system would be
referred to as possible LS while confirmation of diagnosis requires germline testing of
DNA MMR genes (Vasen et aI., 2007; Julie et aI., 2008). Interestingly, many individuals
with tumours demonstrating a mutated DNA MMR gene do not meet the Amsterdam
criteria for family history. Additionally, only about 40% of those that meet the
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Amsterdam criteria have evidence of a mutated DNA mismatch repair gene (Lindor et aI.,
2005).
1.2.6 Familial Colorectal Cancer Type X
The subset of families (60%) fulfilling ACI but not demonstrating MMR deficiency
or an inherited MMR variant have been described as having FCCTX. A separate
classification for these families was deemed necessary following research demonstrating
important differences. Lindor et al. (2005) compared 90 ACI families with MMR
deficiency with 71 ACI families without MMR defects. Proband tumour MSI was used
to assign MMR status. They demonstrated MMR deficient families had a statistically
significant increased risk of developing colorectal, endometrial, gastric, small intestine,
and kidney cancer as expected for LS. The MMR proficient families, however, did not
have an increased risk of cancer at any site. Additionally, the average age of diagnosis of
CRC was later (age 61) in MMRproficient families compared to those with deficiency
whose average age was 49 years old.
While the underlying mechanisms of carcinogenesis have not yet been elucidated, it
is hypothesized that some familial aggregation may occur by chance, some by shared
lifestyle factors, and some by a novel genetic mechanism(s) (Lindor et aI., 2005; Kerber
et aI., 2005). Consequently, FCCTX, which is likely caused by multiple genetic insults, is
recognized as a separate clinical category with a lower incidence of extra-colonic cancers
and later age of onset of colorectal cancer (Mueller-Koch et aI., 2005).
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1.2.7 Common Familial Risk Colon Cancer
A simple family history of CRC has been associated with an increased familial
risk. In fact, those who have a first degree relative with CRC diagnosed after the age of
50 have a two to three times increased risk for CRC. Population based studies have
estimated 20% of all CRC occur in a higher risk setting defined by the occurrence of CRC
before age 50, or a first degree relative pair with CRC (Kerber et aI., 2005). The risk
associated with family history varies greatly according to the age of onset of CRC in the
family members, the number of affected relatives, the closeness of the genetic
relationship, and whether cancers have occurred across generations (Fuchs et aI., 1994;
St.John et aI., 1993). The presence of CRC in more than one family member may be
caused by shared environmental risk factors or even chance but there is growing research
implicating a hereditary component. Common familial CRC is believed to result from a
number of lower penetrant susceptibility genes other than those associated with defined
hereditary syndromes (Jasperson et aI., 2010).
1.3 Clinical Features
LS is inherited in an autosomal dominant pattern. There is a fifty percent risk that
each child of a carrier will inherit the variant and have a high risk of developing
colorectal or other associated extra-colonic cancers. Polyps and colorectal cancers are
predominately in the right side of the colon and there is a small and finite number, unlike
in FAP which may have hundreds to thousands of colonic polyps. Cancer usually
develops at a younger age than that seen in the general population and synchronous and
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metachronous tumours are common (Hampel et aI., 2005). Histologically, tumours are
often poorly differentiated, demonstrate a medullary growth pattern, heavy infiltration of
lymphocytes, or a mucinous or signet ring cell differentiation (Lindor et aI., 2006).
1.4 Colorectal Cancer and Family History
As already identified, a key determinant in the diagnosis of a hereditary cancer
syndrome is a detailed review of the family history. Valuable details include all cancer
types and sites, age at onset, existence of multiple primaries, and any pathological
findings (Lynch & de la Chapelle, 2005). A pedigree offamily members can then be
constructed and evaluated according to the established criteria defining the hereditary
cancer syndromes. Studies evaluating the accuracy of reported clinical data for families
meeting ACI or ACII have shown to be reliable. Love et al. (1985) demonstrated
confirmation of 39 out of 42 reported colonic cancers among first degree relatives.
Sijmons et al. (2000) reported 89% accuracy of reported cancers in 120 families and
Kerber et al. (1998) confirmed II out 17 reported colonic cancers in first degree relatives.
However, not all studies have such proven accuracy and therefore, as recommended by
Katballe et al. (2001), verification of reported cancers and further exploration of family
members should be standard procedure. A hereditary cancer syndrome should not be
rejected simply because ACI or ACII are not fulfilled based on family history alone.
Additionally, basing a diagnosis of hereditary cancer solely on the phenotypical analysis
of the family pedigree can lead to both under- and overestimation of the frequency of the
disease. Small pedigrees should be expanded to reliably exclude or include possible LS,
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and pedigrees of adequate size are needed to eliminate chance aggregation (percesepe et
aI., 1995; Katballe et aI., 200 I).
1.5 Microsate/lite Instability
Microsatellites are sequences of repetitive DNA with repeating units of I to 7 base
pairs. These regions are prone to replication errors, which are normally repaired by MMR
enzymes. If one ofthe MMR enzymes is impaired, such as in LS, the microsatellites
become unstable and will have varying repeat numbers at specific loci. MSI is defined as
any change in length of a microsatellite due to insertion or deletion of repeating units.
Diagnostic criteria (RBG) including a reference panel of five markers were
developed in 1998 to provide a uniform tool to identify and characterize microsatellite
unstable tumours (Boland et aI., 1998). Initially, MSI was classified as low or high.
Tumours were MSI-high if two or more markers were unstable and MSI-low if only one
marker was unstable. Tumours were microsatellite stable (MSS) in the absence of any
unstable markers (Boland et aI., 1998). Much debate has surrounded any clinical
significance between MSI-low and MSS. A review of the literature conducted by de la
Chapelle and Hampel (2010) concluded there was no convincing molecular or
physiologic difference between MSI-low and MSS tumours. Consequently, they
recommended MSI-high be referred to as simply MSI and MSI-low as MSS.
Microsatellite instability is generally a phenotypic marker of defective MMR
involving proteins MLHl, MSH2, MSH6, and PMS2. While it identifies the presence of
defective MMR it does not identify which protein/gene is affected. MSI has been
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considered the hallmark of cancers found in LS but has also been observed in 15-20% of
sporadic colon cancers (Boland, 2007; Poulogiannis et aI., 2010). Consequently, most
CRCs with MSI are not caused by LS. In sporadic colon cancers, this phenotype is
almost entirely due to inactivation of the MLHI gene. This occurs due to
hypermethylation of the promoter region resulting in silencing both copies of MLHI
(Kane et aI., 1997; Poulogiannis et al,. 2010). This acquired silencing is usually found in
older patients but is occasionally also found in younger patients (Gryfe, 2006). About 75-
80% of the CRCs which show MSI (about 10-12% of all CRCs) develop instability due to
this acquired defect and the other 20-25% (3-4% of all CRCs) are due to LS (Boland et
aI., 2008). The characteristic features of sporadic CRC with MSI include the absence of
significant familial clustering, methylation of the MLH1 promoter, and absence ofMLH1
and PSM2 proteins (Boland & Goel, 2010). In LS, there is a corresponding germline
deleterious variant in a mismatch repair gene including MLHl, MSH2, MSH6, PMS2, and
very rarely PMSI. Identification of MSI is useful to identify possible LS families, to
study genetic mechanisms of colorectal carcinogenesis, and for grouping patients in
treatment trials and prognostic marker studies (Esemuede et aI., 2010). It is a valuable
tool to identify LS when families do not meet the clinical criteria and would otherwise be
missed.
Importantly, there is an absence of MSI in a small number of LS tumours. It is
believed this is either due to a false negative secondary to an inadequate number of
markers or tumour cells in the sample, or it is a phenocopy and hence a sporadic tumour
in an individual with LS. Practically speaking, it was recommended that without a strong
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family history, tumours that are MSS from the five-marker Bethesda panel need no
further evaluation for possible LS or somatic inactivation of a MMR gene (de la Chapelle
& Hampel, 20 I0). Despite this fact, 5-20% of LS tumours do not exhibit any MMR
protein deficiency on IHC analysis even though they have lost MMR function as
demonstrated by MSI when testing tumour DNA. While the cause of this discrepancy
remains unknown it could be due to a yet to be identified MMR protein (Poulogiannis et
aI.,20l0).
Three clinical uses have been outlined for the use of MSI status in CRC patients.
Firstly, it is used to identify possible LS, secondly, survival is significantly better in
young patients with MSI and thirdly, these tumours do not have the same response to
chemotherapy as MSS tumours (Boland et aI., 2008).
1.6 DNA MMR System
This system is composed of several proteins that work together to detect and repair
errors during DNA replication. The two families ofproteins involved are the MutS
homologue (MSH), signaling the site of mispairing, and MutL homologue (MLH),
needed to complete the repair process. Functioning as heterodimers, MSH2 is an
obligatory partner often pairing with MSH6 or MSH3. In the MutL family, MLHI is the
obligatory protein which may pair with PMS2, PMSI or MSH3 (Boland et aI., 2008). In
summary, MSH6 can only pair with MSH2 and PMS2 can only pair with MLHI.
Therefore, when MSH2 is inactivated, IHC staining will usually show absence of both
MSH2 and MSH6 proteins, whereas, when MSH6 is lost, MSH2 staining remains positive.
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Similarly, staining loss of MLHi and PMS2 demonstrates inactivation ofMLHi whereas
only loss of PSM2 equates to a mutated PMS2 (see Table A below).
Table A: Loss of Immunohistochemistry Staining in Relation to Affected Mismatch
Repair Gene
Affected Gene
Immunohistochemical Loss of Staining MSH2 MSH6 MLHi PSM2
MSH2 and MSH6
MSH6
MLHi and PMS2
PMS2
Occasional
Rare
(de la Chapelle & Hampel, 2010)
Additionally, MSI activity is impacted by the particular protein absent. If MSH2 is absent
there is no MMR activity and typical MSI is demonstrated. However, if MSH6 is the only
protein absent, some DNA MMR is preserved and typical MSI may not be observed
(Kolodner et aI., 1999).
Demonstrating a deleterious germline variant is the gold standard for diagnosing
LS, however, this is time consuming and expensive. Immunohistochemistry (IHC)
analysis, on the other hand, with/without MSI is inexpensive and is also a predictor ofLS
(Trano et aI., 2010).
1.6.1 MLH] Promoter Methylation
Additional mechanisms for DNA MMR gene inactivation were sought following
the discovery of MSI phenotype in 15% of colorectal cancers from patients lacking a
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significant family history (Hennan, 1998). Widespread changes in DNA methylation had
long been observed in colon cancer leading to the discovery that MMR activity could be
impaired not only by gennline variants in MMR but also by somatic variants and
epigenetic modifications such as DNA methylation which results in gene silencing
(Hennan et al., 1998; Veigl et aI., 1998). In a study by Thibodeau at al. (1998) 40 of42
(95%) sporadic MSI and MMR deficient tumours lacked expression of MLHI indicating
MLHI had a principal role in the phenotype of sporadic MSI CRCs. Subsequent studies
were able to demonstrate aberrant promoter MLHlmethylation was the likely explanation
for the loss of MLHI in these sporadic tumours, and approximately 80-90% of sporadic
MSI CRCs exhibit defective MMR function due to MLHI promoter methylation (Hennan
et aI., 1998; Veigl et aI., 1998). MLHI methylation is functionally equivalent to an
inactivating mutation and produces MSI in tumours not associated with LS.
Consequently, while isolated MSI cannot confirm LS, methylation in combination with
MSI could be useful for discriminating sporadic from LS-associated CRC (Hitchins et aI.,
2007).
Interestingly, MLHI silencing may no longer be considered a mechanism
exclusive to sporadic tumours. A small proportion of LS tumours have also been found to
demonstrate MLHI promoter hypennethylation. Gennline methylation was first reported
by Suter et al. (2004) in two individuals who met clinical criteria for LS but no MMR
gene mutation could be found.
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1.7 Correlation between MSI and MMR
Several studies have examined the concordance between MSI and MMR. In one
study by Mueller et al. (2009) which analysed seventy one CRC cases suspected to be LS
based on family history, twenty-eight were MSI with 96% of these linked to a defect in a
known MMR gene. Overall, consensus in the literature indicates both MSI testing and
the four antibody IHC staining (MLHl, MSH2, MSH6, and PMS2) are fairly equivalent in
predicting germline variants, although the concordance is not perfect. The sensitivity of
IHC predicting MSI has been reported to be about 92% as both tests may miss cases
detectable by the other. For example, IHC can detect MSH6 variant cases that may not
show a high frequency MSI and/or MSI may detect cases that are not covered by the IHC
panel (Shia et aI., 2004). Additionally, 5-20% of Lynch related tumours do not exhibit
any detectable MMR protein expression abnormality despite demonstrating MSI
(poulogiannis et aI., 2010).
1.8 Family History and Molecular Testing
Amsterdam criteria are currently used to identify possible LS patients based on
family history while Bethesda guidelines identify patients who should undergo tumour
molecular analyses for diagnosis. Consequently, if either family history or tumour
analyses are positive, germline testing of DNA MMR genes should be completed to
confirm the diagnosis. (Vasen et aI., 2007; Julie et aI., 2008).
In a prospective study by Trano et al. (20 I0), the performance of clinical guidelines
and molecular tumour tests (microsatellite instability, BRAF mutation, and methylation of
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MMR genes) were assessed to identify possible LS. Three hundred thirty-six tumours
from unselected, consecutively diagnosed CRC patients were analyzed by molecular
tumour tests and the patients were classified according to RGB and ACII. A total of
eighty-seven patients fulfilled the RBG for molecular tumour analyses and eight fulfilled
the ACII. Molecular testing identified twelve tumours as probable LS. RBG had
identified six of them and therefore likely LS, while five of the eight meeting ACII were
not likely LS as they did not fulfill the molecular tumour criteria. They also found that
half of the tumours that were highly suspicious ofLS did not fulfill the RBG.
Another study completed by Syngal et al. (2000) classified seventy families by
clinical criteria and completed mutation analysis ofMSH2 and MLHI by full gene
sequencing. They found the sensitivity and specificity of the ACI were 61 % and 67%.
The sensitivity and specificity of the ACII were 72% and 78%, respectively. The
Bethesda guidelines were the most sensitive with a sensitivity of94% and specificity of
25%. These results considered only defmitive pathogenic variants. In addition,
investigators acknowledged that 40% of families fulfilling Amsterdam criteria did not
have MSH2 or MLHI deleterious variants and thus additional genes remain to be
discovered. In a study by Valle et al. (2007), the clinical utility of MSI to accurately
classify familial clusters of CRC was demonstrated. Only ACI families were identified
from a Spanish national registry and tumours tested. Of those studied, 59.4% were MSI
and classified as LS while the remaining 40.6% were MSS and classified as FCCTX.
MSI families had earlier onset cancer, proximally located tumour, and a tumour spectrum
consistent with LS, whereas most MSS families had only CRC. Additionally, in a study
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by Perea et al. (2010), MSI was demonstrated in 31 % of tumours from young patients.
Clinicopathological features included earlier age of onset, signet-ring cell tumours, more
proximally located tumours, and poorly differentiated tumours with higher mucin
production suggesting LS.
Consequently, distinguishing LS from sporadic CRC requires consideration of a
wide range of evidence: from the family history and examination of the tumours for MSI
and abnormal MMR protein expression, to germ-line mutation analysis (Poulogiannis et
al.,2010).
1.9 Incidence
Incidence of familial CRC has been estimated through the use of family history
and/or molecular characterization. As indicated above, criteria, such as the Amsterdam
criteria, have been developed to provide a scientific basis of comparison across studies.
Additionally, for effective cancer prevention and research it is imperative to have an
accurate knowledge of the cancer frequency.
Numerous studies have been completed estimating the incidence of familial CRC
with the most accurate stemming from the population based studies. By eliminating
selection bias and providing an unselected patient population these studies provide more
reliable estimates of incidence. Using the Amsterdam criteria a variety of population
based estimates ranging from 0.3-5.8% have been reported. In a large, multi-centre study
in Finland by Mecklin et al. (1995), 0.7-2.4% ofCRC was estimated to be familial. A
smaller study, also by Mecklin (1987), which included only one Finnish province,
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demonstrated a higher estimate of3.5-5.5% of all CRC was familial. Similarly, Ponz de
Leon (1993) noted a 3.4-4.5% incidence in Northern Italy. The lowest estimate was
found by Aaltonen et al. (1994) who linked cancer registry with population registry data
and produced an estimate of 0.5-0.9%.
Other attempts at estimation included extrapolation to the larger population from its
incidence in younger patients. Kee and Collins (1991) estimated 1-2.6% would be
familial from an incidence of 6% found in patients less than fifty five years of age.
Finally, Westlake et al. (1991) had the lowest estimate of 0.3% which was extrapolated
from a cohort ofprobands less than age fifty with an incidence of 3.1 %.
Once the MMR genes were identified and some variants shown to cause hereditary
colon cancer, multiple studies completed molecular characterization for incidence
estimates. All used similar methodology including MSI testing of all the CRC patient
tumours followed by mutation detection only when tumours were rnicrosatellite instable
to confirm the diagnosis. Incidence estimates ranged from 0.9-2.7% and included
populations from the Mediterranean region, USA and Finland (Salovaara et aI., 2000;
Aaltonen et aI., 1998; Cunningham et aI., 2001; Ravnik-Glevac et aI., 2000; Percesepe et
aI., 2001; Samowitz et aI., 2001; Goodfellow et aI., 2001).
One ofthe most comprehensive studies, of which the population of this thesis is
included, is that published by Woods et al. (2010). This population based study included
an incident cohort of750 CRC patients from the province ofNewfoundland and Labrador
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(NL). 4.6% were classified as having high familial risk based on fulfillment ACI while
3.6% had germline variants and diagnosed as LS.
1.10 Genotype-Phenotype Variation
Genotype includes one's genetic make-up whereas phenotype refers to the actual
observable characteristic. More specifically, it includes the micro- and macroscopic
expression of an individual's genetic makeup. Many studies have examined correlations
between genotype and phenotype for hereditary colorectal cancer. In this instance, the
value of understanding this relationship lies in the management and appropriate
surveillance of affected individuals. With mutations in either MLH1 or MSH2 a classic
LS phenotype is expected as MMR function is completely lost. When the other proteins
are implicated, however, varying phenotypes exist. For example, an attenuated
phenotype is usually associated with the MSH6 genotype. Endometrial cancer is more
frequent but colorectal cancer is less penetrant and it, as well as other LS cancers, tend to
occur later in life (Hendriks et aI., 2004).
About half of all families clinically defined as LS do not have deleterious variants
in the known MMR genes and are MSS. This active research area involves the possibility
of identifying new CRC susceptibility genes. A mutation in these novel genes may be
associated with a completely different molecular mechanism and, therefore, unable to be
detected by MSI and IHC (Zhang, 2008).
To further support this, a study completed by Rovella et al. (200 I) demonstrated
the existence offamilial MSS CRC. One hundred consecutive CRC patients from a clinic
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in Italy were evaluated through family history, clinical characteristics, and MSI. Eighteen
patients had a positive family history ofCRC in a first degree relative. Thirteen of these
did not demonstrate MSI, had a later age of onset, and had a higher incidence of second
primary tumours relative to non-familial CRCs. No significant difference was found
between the frequencies of extraintestinal cancer sites in the MSS familial pedigrees.
They concluded that the majority of familial CRCs not attributable to known genes are
MSS. As this was not population based, no inferences could be drawn to the general
population. The investigators recommended collection and clinical characterization of
further families for identification of novel genes.
An interesting study by Park et aI. in 2007 looked at the clinicopathological
characteristics of colorectal cancer with family history. They found the number of
patients with MSI tumours was significantly higher in families affected with colorectal or
LS associated cancers than those with other cancers. Seventy percent of the cancers in
first and second degree relatives of colon cancer patients were gastric and colon cancer,
whereas, only 4% were the other LS associated cancers. This study eliminated families
who met the Amsterdam criteria, were FAP, or had vague family histories. The authors
concluded that family history of cancer could be used to predict an underlying familial
MSI is the molecular phenotypic expression of germline MMR deficiency.
Phenotype differences between MSI and MSS families have also been documented. In
the study by Valle et al. (2010), sixty-four Amsterdam I-positive families were included
from a Spanish National Cancer Centre. Three generational pedigrees were constructed
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from family history, tumour samples were collected and examined for MSI status and
MMR protein expression, and MSI families were tested for MMR variants. Twenty-six
families (40.6%) demonstrated MSS and thirty eight (59.5%) were MSI. Of the MSI
families, 30 out of38 had an MMR defect identified and 20 of the 26 MSS tumours
expressed all proteins. Using family cancer history, MSI families had increased incidence
of multiple primary tumours including LS related and other cancers, whereas MSS
families had a predominance of only CRC. Additionally, a study by Perea et al. (2010)
found MSS tumours were associated with diagnosis at a more advanced age. Higher
mortality in patients with MSS tumours suggests MSI tumours have a better prognosis.
The term FCCTX was proposed by Lindor et al. (2005) to describe families who
had a clustering of colorectal cancer but whose tumours lacked any DNA MMR gene
defect. This term did not define the group as having LS. These families did not share the
same cancer incidence as families with LS and relatives in these families had a lower
incidence of CRC and the incidence of other cancers in family members did not appear to
be increased.
1.11 Newfoundland Population
Genetic isolation has decreased considerably in the last century in most European
and North American populations. This is due mainly to the development of extensive
transportation systems and concentration of the population in urban areas. This trend,
however, does not hold for all populations. Some populations still remain genetically
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isolated due to a long history of geographical isolation with minimal immigration. Such
is the case for the island portion of the Canadian province ofNL (Bear et aI., 1987).
The Newfoundland population was originally founded in the late 1700s by about
12,000 settlers from localized areas of southwest England and southeast Ireland. Small,
isolated communities were first established in Conception Bay and the Southern Shore of
the Avalon Peninsula where the local economy was based on the inshore fishery. With
the expansion of the population, new fishing communities were established around
Newfoundland's natural harbours. The migration pattern followed the coastline further
west, on the north and south borders, and eventually up the west and north coasts of the
island. The population has continued to expand with a large percentage still residing in
these isolated coastal communities with approximately 50% ofNewfoundland's
population living in communities of fewer than 2,500 inhabitants even now.
Genetically, the Newfoundland population is ideal for studying genetic diseases
due to its founder history and geographical isolation. Moreover, Newfoundland families
tend to be larger and family records are relatively well detailed allowing family history to
be traced back over several generations.
1.12 Rationale
The goal of this project was to determine the genetic contribution to colorectal
cancer in Newfoundland and Labrador through an analysis of family history and
molecular characteristics ofCRC in the year 1999.
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Just prior to the initiation of this study, a pilot project was implemented examining
colorectal cancer cases diagnosed only on the Avalon Peninsula in Newfoundland during
two years: 1997 & 1998. Conclusions from this study noted a high proportion of cases
with high or intermediate risk family histories (55.1 %), and a majority of cases who
fulfilled Amsterdam criteria had MSS CRC suggesting genes other than MMR may be
involved in hereditary CRC (Woods et al. 2005).
The population base for the current study includes the entire province ofNL,
rather than the Avalon Peninsula, as in the pilot study, and analyzes a larger sample of
incident colorectal cancer cases. As this was a large collaborative study funded by the
Canadian Institute of Health Research (ClliR), more resources were available to increase
study participation and complete family history data, including cancer verification, and
thus provide more accurate and detailed results.
1.13 Background
In 2001, a team of investigators in Ontario and NL developed an interdisciplinary
health research team (lliRT) aiming to advance knowledge of the determinants, the
impact, and the control of colorectal cancer. Six specific research goals were outlined:
1) A case control study to assess whether genes involved in mismatch repair are
associated with CRC risk in Ontario and NL.
2) Among the relatives of probands, the mutation-, sex-, and age-specific cumulative
risks of CRC in MMR gene mutation earners will be estimated and compared with
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similar risks in Ontario families, and these further compared to risks in families with a
Newfoundland founder mutation.
3) In a follow-up study ofCRC patients, the prognostic significance of microsatellite
instability in colorectal tumours assessed in terms of survival among cases from both
provinces.
4) A retrospective study of high risk and low risk individuals, who are relatives ofCRC
patients, to identify factors that may influence the decision to be screened for CRC by
fecal occult blood testing or colonoscopy.
5) The psychosocial and behavioural impact of genetic counselling and testing and of a
diagnosis of CRC in a family assessed among high risk and intermediate risk
individuals.
6) A genetic risk assessment tool for physicians and an information aid for individuals
with a family history of CRC will be developed and evaluated.
(CIHR-IHRT Research Proposal 2000)
For this thesis, data obtained from the incident CRC patients in the fLTst year of
data collection from the IHRT study in NL was analyzed. More specifically, an incident
cohort study over one year was undertaken utilizing both self reported family history and
tumour molecular analyses to determine the genetic contribution to colorectal cancer in
NL.
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1.13.1 CRC-IHRT Results
As outlined in the notes to the reader, results from the five year CRC-IHRT study
have been published by Woods et al. and referenced where applicable. An incident
cohort of750 patients with CRC representing 708 different families from the NL
population was studied. Eligible patients were those diagnosed under the age of75 from
January 1,1999 to December 31,2003. Risk classification was completed as outlined in
this study but additional, more detailed colorectal tumour analyses as well as germline
mutation screening was also completed. They reported 4.6% ofpatients fulfilled ACI and
44.6% fulfilled the RBG. Using high, low, and stable tumour microsatellite
classifications, MSI-H was demonstrated in 10.7% (78/732). Of these, 42 tumours
(53.8%) showed methylation oftheMLHl promoter, 21 (26.9%) were from patients
found to have a deleterious variant in a MMR protein, and the remaining 15 (19.2%)
tumours had no cause identified for the MMR deficiency. Twelve different mutations
were found in six known CRC-related genes and all mutation carriers demonstrated MSI-
H in their CRC tumour. Overall the total proportion ofMMR mutations (Lynch
syndrome) was 2.7%. Additionally, 61 % (17/28) of Amsterdam criteria families did not
have a genetic cause identified and 15 fulfilled FCCTX criteria proposing the existence of
novel mutations in CRC-predisposing genes. Finally, patients from FCCTX families
were found to have a later age of CRC diagnosis and increased occurrence of distal
tumour location compared to patients with LS (2010).
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1.14 Objectives
The main objective of this study was to detennine the genetic basis ofCRC in NL
as defined by family history, molecular pathology of the CRC and molecular genetics in
148 incident cases of CRC aged 20-74 diagnosed in the NL population during one year.
In order to achieve this, I estimated the number of instances of possible LS and FCCTX.
The secondary objective was to further elucidate the phenotype of FCCTX
compared to possible LS. This was achieved by comparing cancer type incidences
between the groups.
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Chapter 2: Materials and Methods
2.1 Study Population Selection
The protocol for the larger study of which this study is a part was designed by
researchers in NL and Ontario. Identification of the population for the entire five year
study was completed by CRC-IHRT research team members prior to initiation of this
thesis following the protocol outlined below. It is important to note, however, that
although I did not personally select the population for this study I did gain a thorough
understanding of the process through reviewing the detailed protocol provided by the
principal investigators, as well as working in conjunction with other team members as a
research assistant on this project prior to enrolling as a masters student.
All colorectal cancer patients aged twenty to seventy-four entered into the NL
provincial tumor registry, diagnosed from January 1, 1999 through December 31,2003,
were retrieved. Unregistered cases were identified through review of hospital ICD9
codes and through the provincial death statistics. Demographic information including
sex, age, address, telephone numbers, as well as attending physicians, and other related
cancer histories were extracted from the registry. Corresponding tumour pathology
reports of these patients registered with the provincial cancer registry in the province of
NL were retrieved and reviewed by expert pathology team members. The following
pathological inclusion and exclusion criteria developed by the principal investigators
were applied to determine which patients were forwarded to the recruitment team.
-----------I( 29 )~--------
2.1.1 Inclusion Criteria
Any tumour described as adenocarcinoma (including any mention of signet ring
cells but not including carcinoid), adenosquamous, undifferentiated, poorly differentiated,
small cell carcinoma, or any combination of the previous from all parts of colon, rectum
and anal canal were included. Squamous cell carcinoma was only included ifit was
definitely arising from the rectum or colonic mucosa. Inclusion of pseudomyxoma was
only included if accompanied by adenocarcinoma.
2.1.2 Exclusion Criteria
Any tumour that was squamous cell carcinoma of the anal canal, lower rectum or
lacked certainty if it originated from colonic or rectal mucosa were excluded.
Additionally, all usual carcinoid tumours including goblet cell carcinoid and all
pseudomyxoma that were not accompanied by adenocarcinoma were excluded.
2.1.3 Proxy Identification
For individuals who were deceased, a proxy (next of kin) was identified and
contacted, by the recruitment team, to act on the patient's behalf. Names were available
through the provincial cancer registry, the physician's office, or through a follow up
phone call to the proband's family. First contact with the proxy was made through the
proband's physician unless the proxy was identified during a follow up call; at which time
verbal consent was obtained.
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2.1.4 Recruitment
Two hundred and sixty-two cases ofCRC were registered in the province ofNL
during the year 1999 with one hundred forty-eight having completed family history
questionnaires (FHQ) required for this analysis. Figure 1 summarizes the recruitment
process. All two hundred sixty-two pathology reports were obtained through the
provincial cancer registry. A total of thirty two were excluded: twenty-five were
excluded because there was no resection of the tumour, two because the occurrence was
the result of metastatic disease, one was due to a wrong diagnosis, one was not a NL
patient, and for three cases no reason was noted in the database by the pathology team
member. Of the remaining two hundred thirty eligible participants contact could not be
made with three patients; no current address or contact information could be found for
one, another was deceased and no doctor or next oflein identified, and in the third
instance the doctor said the patient was not suitable for the study and refused to send the
contact letter. One hundred ninety-six patients (83.3%), of the two hundred twenty-seven
patients contacted, were initially willing and FHQs were mailed. Forty-eight (24.5%)
patients declined participation after receiving the FHQ while the remaining one hundred
forty eight questionnaires were returned (75.5%). Overall, for the first year of data,
98.7% of those eligible were contacted and 64.3% of those eligible completed the FHQ.
After collection of the information required for this study, eight probands chose to
withdraw from the CRC-IHRT study. Permission was granted from all of these
individuals to use any already collected data including molecular analysis of the tumour
blocks. He/she did not wish to be contacted in the future to complete any further aspects
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Total 1999
Cases
2 metastatic disease
1 wrong diagnosis
I-not from NL
3-noreasonreportedby
pathology team
3-unabletocontact:
noaddress,no
NOK,docrefused
°eight withdrew from the study but permission was obtained for use of their data.
Figure 1: Summary of Recruitment of Study Participants
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of the CRC-IHRT study. Consequently, 75.5% of those willing and 64.3% of those
eligible are included in this study.
2.2 Data Collection
Jparticipated in all aspects ofdata collection however my research was completed as a
member ofthe recruitment team and was not restricted to only participants diagnosed in
1999.
Initial contact with participants was made through the proband's physician. More
specifically, each proband identified by the provincial cancer registry had a list of
physicians associated with him/her. After participation agreement from the acting
physician, a patient-addressed letter and reply card were forwarded by the recruitment
team to be signed and mailed on the study's behalf. The self-addressed reply card was
returned by the physician to indicate the invitation letter had been mailed. Two weeks
post mail-out; the patient was contacted by a registry team member and asked whether
he/she was interested in participating. If willing, the recruitment team mailed the
participant a package which included the consent forms, details of the study as well as the
FHQ. Once consent was obtained, participants completed the FHQ, which was used to
assess familial risk, and samples of his/her tumor block were collected by the molecular
team to undergo molecular analysis including microsatellite instability testing and
immunohistochemical staining.
Demographic information including sex, mean age of diagnosis, CRC tumor site,
and residence for non-participants was also collected from the registry which I compiled
into a working data set of all probands diagnosed with CRC during the year 1999. I
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compared this information to that of participants to determine the representativeness of
my sample.
2.2.1 Family History Questionnaire
This questionnaire was designed so a three-generation pedigree could be
constructed. More specifically, questions were asked regarding the family cancer history
of grandparents, parents, siblings, and children. In addition, names of other family
members who had been diagnosed with cancer and age of cancer diagnoses were
requested. Following this mail out, regular follow up took place via phone to increase the
response rate. A phone or in-person interview was available and a toll free phone line
was accessible to all participants if assistance was required. Upon receipt of the FHQ, a
family pedigree was constructed using the computer package Cyrillic 3.
2.2.2 Verification ofCancers
This portion ofthe methods was completed in partnership with the genetic counselor
Angie Batstone.
In order to ensure accuracy of the history provided and subsequent risk
assessment, verification of all hereditary associated cancers in relatives was attempted in
first and second degree relatives. The cancers included were colon, endometrial, liver,
stomach, brain, and ovary. Any non-associated and unknown cancers were only
attempted to be verified if they directly affected risk classification. For those relatives
who were alive, a family address sheet was mailed to the proband asking him/her to
contact relatives requesting permission for the research team to contact the relative. For
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those who were deceased and for those whom permission was obtained, a request for
information (ROJ) form was mailed which required signature of the living relative or
from the next of kin of those who were deceased. Upon receipt of the signed ROI,
relevant medical records were requested. Two hundred seventy-seven reported cancers
were attempted to be verified, of which 44% were successful (see section 3.2.5 for
detailed results). Some families had been previously identified by the Provincial Medical
Genetics Program (PGMP), which is responsible for all the regional genetic screening.
This data was accessed, with permission, where applicable for any cancers that were
previously confirmed. Verification was often not possible due to inability to obtain
records of cancers diagnosed outside the province or those diagnosed before records at
the corresponding hospitals were retrievable. In addition, some probands did not have
any contact with the next of kin, or relatives declined participation preventing cancer
verification.
2.2.3 Health Regions
At the time of this study, NL had six distinct health regions: St. John's, Eastern,
Central, Western, Grenfell and Labrador. The boundary of each region was defined by
the Department of Health and illustrated in Figure 2. Individuals from Grenfell and
Labrador health regions were combined into one group. Geographically these two
regions are adjacent and while they may be the largest in size they represent the fewest
number ofparticipants. Each proband was assigned to the health region corresponding to
the personal address provided by the provincial tumor registry which was recorded at the
time of registration.
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Figure 2: Six Defined Health Regions of Newfoundland and Labrador
http://www.statcan.gc.ca/concepts/health-sante/maps-cartes/nfld-eng.jpg
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2.3 Family History Risk Assignment
A three generation pedigree was constructed for each participant according to
reported cancers, and risk assignment (the likelihood he/she might be carrying an
inherited deleterious variant) was conducted. I determined familial risk classification in
accordance with intemationalIy recognized criteria as outlined by the CRC-IHRT study.
In partnership with Dr. Jane Green, alI pedigrees were reviewed for accuracy of risk
classification and any changes to risk classification folIowing family history updates were
completed under the direction of Dr. Jane Green.
2.3.1 High Risk
Family history high risk families were classified according to ICG-HNPCC
established criteria for ACI and ACII (see 1.2.1 and 1.2.2). A third classification of high
risk was defmed by altering the age criteria and tumor type for ACII. This was classified
as age and cancer-modified Amsterdam criteria (ACMAC) and is defmed by a family
meeting alI Amsterdam II criteria with the age limit raised from 50 to 60 and the extra-
colonic tumor list expanded to include alI the tumors of the RBG (see 1.2.4). ACMAC
incorporated high risk families that had been excluded based on the arbitrary age and
tumour list of the Amsterdam criteria but clearly demonstrated characteristics of
autosomal dominant disease; every affected individual has an affected biological parent,
there is no skipping of generations, and males and females have an equalIy likely chance
of inheriting the mutant allele and being affected.
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2.3.2 Intermediate Risk
Intermediate risk (IR) was assigned to families who did not fulfill ACI or II but
did fulfill the clinical criteria of the RBG. The use of the RBG to confer an intermediate
familial risk classification was part of the design of the CRC-IHRT study. While they are
the third clinical criteria to identify possible LS families, the RBG are the least stringent
to identify those with germline variants in one of the MMR genes. They were originally
designed to identify individuals whose colorectal tumours should be tested for MSI, not
specifically identify families that meet clinical criteria for LS (see section 1.2.4 for
specific criteria). Additionally, for the purposes of this study, criterion 3 (MSI-histology
of tumours) was not utilized. This criterion is based on pathology analysis that is not
routinely assessed or reported in practice. Those that satisfied more than one criterion
were also classified according to the criteria most suggestive of a Mendelian inheritance
pattern. Specifically, compared to the other criteria, revised Bethesda criteria 4 and 5
have the highest family frequency ofLS associated or CRC cancers represented in
successive generations thereby most suggestive of a Mendelian inheritance pattern.
Therefore, revised Bethesda 4 or 5 criteria was the sole classification when these criteria
were met in addition to others.
2.3.3 Low Risk (Sporadic)
All remaining probands who did not meet either high or intermediate risk criteria
were categorized as low risk. These families were further classified as informative or
non-informative according to the reported family history based on the definition outlined
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in the similar study completed for the Avalon Peninsula. lnfonnative families were
defined as those with six or more family members in two successive generations
potentially at 50% risk of inheriting CRC who had survived until at least age 60. As LS
follows a Mendelian inheritance pattern and age of onset is usually before sixty, this
definition ensures a pedigree has enough infonnation to make an accurate risk
classification based on the infonnation available (Curtis, 2003).
2.4 Genetic Counseling
As this area requires specialized training I shadowed and assisted the genetics nurse to
learn the procedure. Letters to the patients included in this study were reviewed as well
as the necessary screening protocols.
All participants were offered genetic counseling. Low risk patients were mailed a
letter outlining their risk and recommending case specific screening strategies as well as
offering counseling. High and intennediate risk patients were invited directly for
counseling and then mailed a letter which outlined their risk. Each chart was reviewed by
genetics nurse Angie Batstone and Dr. Jane Green.
2.5 Tumor Blocks
Tumours in paraffin blocks were requested by the pathology team for all
participants after we advised consent had been received. Hospitals where the patient had
undergone surgery were contacted with the corresponding tumor identification code.
They forwarded a sample of the tumor and nonnal tissue. Regular consultations occurred
with the pathology team regarding tumours received and those outstanding.
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2.6 Molecular Analysis
All tumours were analyzed for microsatellite instability, by Dr. Roger Green's lab,
and protein expression using immunohistochemistry staining, by Dr. Des Robb's lab.
Information for this study was received after being compiled by Dr. Roger Green in a
confidential excel spreadsheet.
2.6.1 Microsatellite Instability
Five microsatellite markers were used to classify all tumours as microsatellite
stable or unstable by comparing matched normal and tumor DNA. The markers used
were BAT25, BAT26, D2S123, D5S346, D17S250. In this study, tumours were
classified as microsatellite stable if fewer than two markers demonstrated instability or
microsatellite high if two or more markers were unstable. MSI-Iow has been previously
used when one marker was found to be unstable however, as outlined in section 1.5, no
convincing molecular or physiologic difference has been found between MSI-Iow and
MSS tumours and therefore MSI-high is referred to as simply MSI and MSI-Iow as MSS.
2.6.2 Immunohistochemistry Staining
Immunohistochemical staining was performed on each tumor for three mismatch
repair proteins; MLH1, MSH2, MSH6. Testing for PMS2 was not completed for this
study. Ifprotein expression was positive, the tumor was classified as having no gene
dysfunction for that particular protein. If the tumor did not exhibit protein expression the
tumor was classified as having gene dysfunction for that particular protein.
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2.7 Genetic Classification
Using IHC results, I further classified high risk families as probable LS, FCCTX
or age modified FCCTX. Families ofpatients with tumours demonstrating MMR protein
deficiency were classified as possible LS, while those who fulfilled AC and had no MMR
deficiency were referred to as FCCTX. Finally, families of patients whose tumours
expressed all proteins and fulfilled the ACMAC high risk criteria were considered age
modified-FCCTX.
Families can only be definitely classified as LS when a deleterious variant is
found in a MMR gene. While this analysis was being completed by another molecular
team only MSI and IHC results were designed to be included in this study as the basis for
genetic classifications. Although the detailed mutational analysis is beyond the scope of
this thesis, results from the five year study in its entirety have since been published by
Woods et al. (201 0) and reference has been made where applicable. Access to the
detailed results was not part of the data collection for this thesis.
2.8 Analysis
Molecular information and family history were compiled and analyzed using the
Statistical Package for Social Sciences (SPSS). Comparison of willing participants to
those that declined was completed using chi-square to compare to sex, CRC tumour site
and residence and independent samples t-test to compare mean age of diagnosis. Chi-
square analysis was also used to test if there was any difference between health regions in
the frequency of low, intermediate or high risk families. No more than 20% of the cells
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had an expected frequency less than 5, meeting the assumption for the chi-square test of
independence. Significance was set at p<O.05.
Clinical cancer phenotype was also compared between possible LS and FCCTX
families. First and second degree relatives were included to compare age of diagnosis
and frequency of occurrence of CRC and associated hereditary cancers. Age at diagnosis
for those with cancer occurrence or age of last follow up for those without cancer was
used for analysis. Hereditary cancers were those defined by the RBG including
colorectal, endometrial, stomach, ovarian, pancreas, ureter, renal pelvis, biliary tract,
brain (glioblastoma), small intestine, sebaceous gland adenomas and carcinomas and
keratocanthomas. Kaplan-Meier time-to-event survival curves were constructed to
demonstrate differences in age of cancer onset between possible LS and FCCTX families.
Statistical significance was determined using Mantel-Cox and Breslow with p<O.05.
2.9 Ethical Considerations
Approval for the larger CRC-IHRT study was obtained from the Human
Investigations Committee at Memorial University ofNewfoundland. All identified
individuals were entered into a restricted, password-protected database and all
corresponding files kept in a locked filing cabinet. All individuals were initially
contacted by their physician and informed consent was obtained only after he/she
demonstrated an interest in participation. Participants were free to withdraw at any time
or to decline to complete any portion of the study. Completing requested questionnaires
and/or contacting requested family members may have been time consuming or difficult
---------i( 42 )1-----------
for the patient and therefore was completed at the participant's convenience with or
without assistance. To maintain patient confidentiality all molecular analyses were
completed using only corresponding patient study identification numbers.
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Chapter 3: Results
3.1 Characteristics ofParticipants
Of the one hundred forty-eight willing participants providing complete
infonnation, ninety (60.8%) were living and fifty-eight (39.2%) were deceased and
represented by proxies. There were sixty-one (41.2%) females and eighty-seven (58.8%)
males. The age range of CRC patients was 20-74 years with a mean of 61 years of age.
The total population at risk in 1999, aged 20-74, was five hundred forty thousand, eight
hundred ninety-five (540,895) for an incidence of colon cancer of 0.0484%. Distribution
of incidence according to the five defined health regions ofNL revealed forty-six (31.1 %)
participants were from the St. John's region, twenty-nine (19.6%) from the Eastern region
(exclusive of StJohn's), forty-three (29.1%) from Central, nineteen (12.8%) from
Western, and eleven (7.4%) from the Grenfell/Labrador region. The tumour site for one
hundred (67.6%) of the participants was the proximal colon and for forty-eight (32.4%)
the distal colon including the recto-sigmoid, rectum, and anus.
Table I summarizes the characteristics ofparticipants and non-participants. No
significant differences between participants and non-participants were found when sex,
mean age of diagnosis, CRC tumour site, and residence were compared, suggesting the
study population for this thesis is representative of the whole population.
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Table 1: Characteristics of Participants (n=148) and Non-Participants (n=82).
Statistical comparison of participants to non-participants using chi-square and independent
samples t-test to test for recruitment bias.
Participants Non-Participants
Alive 90(60.8%) 44(53.7%)*
Deceased 58(39.2%) 38(46.3%)*
Male 87(58.8%) 48(58.5%)*
Female 61 (41.2%) 34(41.5%)*
Mean Age CRC diagnosis 61 62.6 **
Age Range CRC diagnosis 20-74 22-74 **
Tumour Site
Colon 100(67.6%) 53(64.6%)*
Rectum, Recto-sigmoid, Anus 48(32.4%) 29(35.4%)*
Place of Residence
St. John's 46(31.1%) 25(30.5%)*
Eastern 29(19.6%) 14(17.1%)*
Central 42(29.1%) 24(29.3%)*
Western 19(12.8%) 15(18.3%)*
GrenfelULabrador 8 (7.4%) 4 (4.8%)*
*p>0.05 between groups, Chi-Square Analysis
**p>0.05 between groups, Independent Samples T-test
--------~( 45 )1---------
3.2 Family History Study
3.2.1 Risk Classification
A three generation pedigree was constructed for each participant and
familiaVclinical risk was assigned according to family reported cancers. Nine probands
were found to be relatives of one another and required unique risk consideration: four
were fust degree relatives (siblings), two were second degree relatives (uncle and
nephew), two were fourth degree relatives, and one pair of the siblings also had a third
degree relative who was a proband. The first, second, and third degree relatives were
considered to have the same familial risk and therefore were only entered once in the
family history analysis. The fourth degree relatives, however, had different maternal
versus paternal sides at risk and it was determined by Dr. Jane Green that these probands
required separate risk classifications and therefore were independently counted.
Consequently, while there were one hundred and forty eight probands, there were a total
of one hundred and forty-four families reviewed for family history risk classification
(Table 2).
Eighteen families (12.5%) were classified as high risk for possible LS. Four
(22.2%) of these fulfilled ACI and fourteen (77.8%) fulfilled ACMAC.
Forty-eight (33.3%) families were classified as intennediate risk according to the
RBG, exclusive of the eighteen high risk families. As previously indicated, Bethesda
criterion 3 (colorectal cancer with MSI-H histology diagnosed in a patient < 60 years of
age) was not utilized since risk classification in this study was according to family history
-----------t( 46 )1----------
Table 2: Frequencies of Family History Classifications Organized by Risk
Category.
Families %
High Risk 18 12.5
Amsterdam I 4 2.8
Amsterdam II 0 0
Age/Cancer Modified Amsterdam 14 9.7
Intermediate Risk 48 33.3
Bethesda 1 10 6.9
Bethesda 2 5 3.5
Bethesda 4 3 2.1
Bethesda 5 16 11.1
Bethesda 1&5 5 3.5
Bethesda 1&2&5 1 0.7
Bethesda 2&5 6 4.2
Bethesda 4&5 1 0.7
Bethesda 2&4 1 0.7
Low 77 53.5
FAP 1 0.7
TOTAL 144 100
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only. Sixteen (33.3%) probands were IR based on having two first or second degree
relatives with RBG defined tumours (Bethesda criterion 5, B-5). Three (6.3%) probands
met Bethesda criterion four (B-4) based on having a first degree relative with a RBG-
defined cancer less than 50 years of age. Five (10.4%) fulfilled Bethesda criterion two
(B-2) based on the presence of synchronous or metachronous RBG defmed cancers, and
ten (20.8%) fulfilled the criterion of a CRC tumour in a proband less than 50 years of age
(Bethesda criterion 1, B-1). Fourteen probands (29.2%) classified as IR fulfilled multiple
Bethesda criteria. Six met B-2 and B-5, one met B-4 and B-5, one met B-2 and B-4, and
one met B-1, B-2, and B-5. Final classification was according to the criteria most
suggestive of a Mendelian inheritance pattern, specifically using the criteria with the
highest frequency of RBG defmed or CRC cancers in successive generations. Any
proband that satisfied Bethesda criteria 5 in addition to others received Bethesda 5 as
his/her sole risk and the one proband satisfying Bethesda 2 and 4 was classified as
Bethesda 4 (Table 3). Overall, twenty nine (60.4%) families met B-5, four (8.3%) met B-
4, five (10.4%) met B-2 and ten (20.8%) met B-1.
Seventy seven (53.5%) families did not meet high or intermediate risk and were
classified as low risk.
One family (0.7%) was a known FAP family as identified by Dr. Jane Green.
FAP is a known hereditary CRC syndrome associated with theAPC gene and therefore
was not risk classified as high, intermediate or low and is represented as a family history
classification only.
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Table 3: Final Family History Classification Frequencies. Intermediate risk
families fulfilling more than one Bethesda criteria were classified according to the
criteria most suggestive of a Mendelian inheritance pattern.
Families %
High Risk 18 12.5
Amsterdam I 4 2.8
Amsterdam II 0 0
Age/Cancer Modified Amsterdam 14 9.7
Intermediate Risk 48 33.3
Bethesda 1 10 6.9
Bethesda 2 5 3.5
Bethesda 4 4 2.8
Bethesda 5 29 20.1
Low 77 53.5
FAP 1 0.7
TOTAL 144 100
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3.2.2 Low Risk Family Informativeness
Fifty-two low risk families (67.5%) were classified as informative and twenty-five
(32.5%) uninformative. Of the twenty-five uninformative families, twelve had fewer than
six family members in two successive generations potentially at 50% risk of inheriting
any autosomal dominant cancer, five had fewer than six family members at risk that had
survived to sixty years of age or developed cancer, and eight had insufficient family
history.
3.2.3 Distribution ofFamily Risk According to Provincial Regions
Each participant was assigned to one of the five health regions in Newfoundland
and Labrador according to the proband's address provided at the time of inclusion into the
study. St. John's, Eastern, Central, Western, and Grenfell/Labrador health regions were
used whose boundaries follow those outlined by the Department of Health. Table 4
summarizes incidence rates of colon cancer in 1999 according to health region for ages
20-74; forty-six cases (31.1 %) were found in the St. John's region, twenty-nine (19.6%)
in the Eastern, forty-two (29.1%) in Central, nineteen (12.8%) in Western, and eleven
(7.4%) in the Grenfell/Labrador region. Regional incidences per 100,000 were calculated
and found to be 36.0, 36.4, 58.9, 31.9, and 8.6 respectively. Using chi-square, there was
no significant difference between regional incidence rates with p = 0.406. Further
characterization using family history risk classification (high, intermediate and low risk)
according to health region was also completed and is summarized in Table 4A. Of the
total number of colon cancers per health region, Western had the highest frequency
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Table 4: Incidence Rates of Colon Cancer in 1999 According to Provincial Region for
ages 20-74. Statistical comparison of incidence rates of colon cancer according to NL
provincial health regions for ages 20-74 using chi-square.
St.John's Eastern Central Western Grenfell/
Labrador
Total Colon
Cancers 46(31.1%) 29(19.6%) 42(29.1%) 19(12.8%) 11(7.4%)
Population
At Risk age
20-74 127,682 79,753 72,980 59,644 28,492
Incidence
Rate* 36.0/1 00,000 36.4/100,000 58.9/100,000 31.9/1 00,000 8.6/100,000
*p=OA06
Source: Statistics Canada, Population Estimates, 1999. Prepared by the Research and Evaluation Department
at the Newfoundland and Labrador Centre for Health Information.
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Table 4A: Comparison of Frequencies of Family History Risk Classifications
Between Provincial Health Regions. Statistical comparison of high, intermediate and
low familial risk frequencies between NL health regions using chi-square. Risk
frequencies are calculated per region using the total number of regional colon cancers as
the denominator.
St.John's Eastern Central Western Grenfell/
Labrador
TotalCRC 46 29 42 19 11 p-value
High 6(13.0%) 4(3.8%) 3(7.1%) 4(21.1%) 1(9.1%) 0.999
Amsterdam! 2 0 I I 0
ACMAC 4 4 2 3 I
Intermediate 13(28.2%) 9(31.0%) 16(38.1%) 8(42.1%) 6(54.5%) 0.406
Low 27(58.7%) 16(55.2%) 23(54.8%) 7(36.8%) 4(36.4%) 0.406
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(21.1%) of high risk family history CRC; while St. John's had the highest frequency
(58.7%) of low risk family history classified CRC. Although no statistically significant
differences between incidence were found (p>O.05) when the frequencies of high,
intermediate, and low family history risk classifications were compared between the five
health regions, clinically these differences may be important.
3.2.4 Summary ofFamily History Reported Cancers
Reported cancers in first and second degree relatives of the one hundred forty-
eight probands are summarized, according to assigned family history risk, in Tables 5 to
8. CRC was the most frequently occurring tumour in the high and intermediate risk
families while breast and lung were most common in the low risk.
Of seventy-seven relatives in the ACI families, twenty-five (32.5%) were reported
to have developed cancer. The mean age for occurrence was 45.7 years with a range of 7-
73 years of age (three relatives had unknown age of occurrence). A total of eight
different cancer types and one unknown were reported with the most common extra-
colonic tumour being endometrial. Nine relatives were reported as having two cancers
and were counted separately in the frequency table. Therefore, a total of thirty-four
cancers were reported (Table 5).
The ACMAC family history risk group had a total of two hundred sixty-eight
relatives. Sixty-eight (25.4%) were reported as developing cancer with the mean age of
occurrence being 59.8 years and the range 11-89 years of age (nine relatives had an
unknown age of occurrence). Twenty-two types of cancer were reported with stomach
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Table 5: Frequency of Family History Reported Cancers for Amsterdam Criteria
I Families According to Specific Cancer Type Categories (n = 4).
CancerTvoe
CRC
AMSTERDAM II
Endometrial
small bowel
Ureter
renal pelvis
BETHESDA
Stomach
ovary
Pancreas
biliary tract (Iiver,gallbladder,bile duct)
brain (glioblastoma)
sebaceous gland
OTHER
Skin
Breast
Prostate
UNKNOWN
TOTAL
# reported
15
34*
% of reported
44.1
23.5
17.6
11.8
2.9
100
*Ninerelatives were reported as having two primary cancers:
1 CRC and ovary
2 CRC and small bowel
2 CRC and endometrial
1 endometrial and breast
1 skin and prostate
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Table 6, Frequency of Family History Reported Cancers for Age and Cancer
Modified Amsterdam Criteria Families According to Specific Cancer Type
Categories (n = 14).
Cancer Type
CRC
AMSTERDAMTI
Endometrial
small bowel
Ureter
renal pelvis
BETHESDA
Stomach
Ovary
Pancreas
biliary tract (liver,gallbladder,bile duct)
brain (glioblastoma)
sebaceous gland
OTHER
Skin
Lung
Breast
Cervix
Prostate
Kidney
Leukemia
Bone
Lymphoma
Thyroid
Neuroblastoma
UNKNOWN
TOTAL
# reported
28
I
o
o
o
13
7
3
I
2
o
o
25
73*
% of reported
38.4
1.4
17.8
34.2
8.2
100
*Fourrelatives were reported as having multiple primaries:
1 CRC and ovary 1 CRC, stomach, and prostate
1 CRC and kidney 1 CRC and prostate
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Table 7: Frequency of Family History Reported Cancers for Intermediate Risk
Families According to Specific Cancer Type Categories (n = 48).
Cancer Type
CRC
AMSTERDAM II
Endometrial
small bowel
Ureter
renal pelvis
BETHESDA
Stomach
Ovary
Pancreas
biliary tract (Iiver,gallbladder,bile duct)
brain (glioblastoma)
sebaceous gland
OTHER
Skin
Lung
Breast
Cervix
Prostate
Kidney
Leukemia
Bone
Lymphoma
Brain
tongue/mouth/throat
Testicular
Bladder
Myeloma
UNKNOWN
TOTAL
*eleven relatives reported with multiple cancers:
I kidney and lung I stomach and lung
3CRCandlung I breast and bladder
# reported % of reported
53 31.9
5 3.6
3
I
I
o
32 18.8
21
2
4
5
o
o
80 39.1
10
21
18
4
6
3
1
2
3
2
6
1
I
2
9 6.5
174* 100
I stomach and breast 2 liver and lung
I stomach and skin I CRC, stomach and lung
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Table 8: Frequency of Family History Reported Cancers for Low Risk
Families According to Specific Cancer Type Categories (n = 77).
Cancer Type
CRC
AMSTERDAMll
Endometrial
small bowel
Ureter
renal pelvis
BETHESDA
Stomach
Ovary
Pancreas
biliary tract (liver,gallbladder,bile duct)
OTHER
Skin
Lung
Breast
Cervix
Prostate
Kidney
Leukemia
Bone
Lymphoma
Thyroid
Brain
Bladder
Myeloma
tongue/throat
Testicular
Esophagus
vocal cords
pseudomyxoma peritonei
UNKNOWN
TOTAL
# reported
19
4
o
o
o
25
15
1
2
7
122
14
24
24
6
12
5
5
4
6
2
I
6
2
7
I
I
I
1**
22
192*
% of reported
9.9
2.1
13
63.5
11.5
100
*five relatives were reported with multiple cancers:
I stomach and vocal cords I kidney and lung
I liver, pancreas, stomach I stomach and prostate
***primarywas confirmed as unspecified but stomach excluded
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being the most common extra-colonic cancer. Four relatives were reported as having
multiple cancers to make a total of seventy-three reported cancers (Table 6).
Eight hundred sixty relatives were included for the IR families. Of these, one
hundred seventy, (20%), were reported as developing cancer. The mean age of diagnosis
was 60.7 years with a range of 22-90 years of age. Age of diagnosis was missing for
forty-one relatives. Twenty-two different types of cancer were reported with the most
common extra-colonic occurrence being stomach. Eleven relatives had multiple cancers
to make a total of one hundred eighty-two reported cancers (Table 7).
Low risk families had a total of one thousand two hundred eighty-three relatives
included. One hundred eighty-five (14.4%) relatives were reported as developing cancer
with a mean age of63.4 years for occurrence and a range of 18-91 years of age (age of
diagnosis was missing for forty relatives). Twenty-seven different types of cancer were
reported and the most common extra-colonic cancer was lung. Multiple cancer
occurrences (one with three cancers and five with two) were reported for six relatives
making a total of one hundred ninety-two reported cancers (Table 8).
3.2.5 Confirmation ofFamily Reported Cancers
All reported cancers were revie.wed with the genetic counsellor and confirmation
attempted only for those directly linked to the patient's family history risk classification,
such as colorectal or other ACll cancers. Of the four hundred forty-seven first and
second degree relatives reported as having cancer in this study, confirmation was
attempted for two hundred seventy-seven (62.0%). Confirmation was not required for
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one hundred seventy relatives (38%). One hundred and twenty-three (44.4%) of the
attempts were successful, leaving one hundred fifty-four (55.6%) unable to be confmned.
Ninety-eight of those confmned were through direct contact with the patient, or next of
kin for those deceased. An additional twenty-five were confirmed through the PMGP
using previously identified families. The main reasons for lack of confirmation for the
55.6% failed attempts included, no records being available (67), the requested ROI forms
were not completed (32), and refusal to give permission to review medical records (30).
Other reasons included: patient withdrew (6), records not obtainable from the hospital
(10), and no next of kin available (9). See Table 9 for a summary of these results.
Confirmation status was also organized according to family history risk
classification and is summarized in Table 10. Of the ninety-three relatives reported with
cancer for high risk families, forty-eight (51.6%) were confmned, twenty-nine (31.2%)
not confmned and sixteen (17.2%) did not require confirmation. One hundred sixty-nine
IR family members with cancer were identified of which forty-nine (29.0%) were
confirmed, eighty (47.3%) unable to be confirmed, and forty (23.7%) cancers not
requiring confirmation. One hundred eighty-five low risk relatives with cancer were
reported with confirmation for twenty-six (14.1 %) of the seventy-one cancers attempted
while one hundred fourteen (61.6%) did not require confirmation. As previously
indicated, we only attempted cancer confirmation for relatives that directly impacted risk
classification.
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Table 9: Summary of Cancer Confirmation for Family History Reported Cancers for
First and Second Degree Relatives.
N
No Confirmation Attempt 170
Confirmed 123
Proband 98
PMGP 25
Not Confirmed 154
No records 67
Not completed 32
Permission not given 30
No next of kin 9
Can't obtain from hospital 10
Patient withdrew 6
TOTAL 447
% of TOTAL
38
27.5
34.5
100
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Table 10: Summary of Cancer Confirmation for Family History Reported Cancers
for First and Second Degree Relatives According to Family History Risk
Classification.
High IR Low
Confirmed 48(51.6%) 49 (29.0%) 26(14.1%)
Not Confirmed 29(31.2%) 80(47.3%) 45(24.3%)
No Confirmation Attempt 16(17.2%) 40(23.7%) 114(61.6%)
TOTAL 93 169 185
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3.3 Molecular Laboratory Study
3.3.1 Tumour Collection
One hundred forty-three tumours were collected for one hundred forty-eight
probands/one hundred forty-four families. As only five tumours were unable to be
collected, 96.6% of probands representing one hundred forty families (97.7%) had
tumours for molecular analysis. Of the five unattainable tumours, one was for a proband
in the age modified FCCTX group, one for an IR proband (Bethesda criterion 5) and three
for probands in the informative low risk group (Figure 3).
3.3.2 Microsatellite Analysis
Analysis was complete for one hundred forty-one (98.6%) tumours and
incomplete for two (1.4%); one from a proband in the age modified FCCTX group and
one for an IR proband. Table II summarizes the results. One hundred twenty-six
(88.1 %) tumours were microsatellite stable (MSS) and fifteen (10.6%) had microsatellite
instability.
3.3.3 Immunohistochemistry Results
Immunohistochemistry analysis was completed for one hundred forty-three
(100%) tumours and is summarized in Table 12. One hundred twenty-four tumours
(85%) had positive expression for all three of the proteins. Thirteen cases (9.1%) had
negative expression for one protein and positive expression of the remaining proteins;
eleven (7.7%) were MLHl negative including one having inconclusive staining for
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Tumours
Collected
143
• 2 probands from the same family
Figure 3: Summary of Tumour Collection According to Family History
Classification
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Table 11: Summary of Microsatellite Analysis Results for All Tumours Collected.
N 0/0 % Total
Complete
MSS 126 89.4 88.1
MSI-H 15 10.6 10.5
Total 141 100 98.6
Incomplete 1.4
TOTAL 143 100
---------1[ 64 )~--------
Table 12: Summary of Immunohistochemistry Analysis Results for All
Tumours.
N %
Full Protein Expression
Protein Absence
MLHl
MSH2
MSH6
Total
124
11*
1
1
13
86.7
7.7
0.7
0.7
9.1
Inconclusive Stainin with remainin roteins havin ositive ex ression
MLHI
MSH6
MLHl&MSH6
Total
TOTAL 143
0.7
2.8
0.7
4.2
100
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MSH6, one (0.7%) deficient for MSH2, and one (0.7%) deficient for MSH6. A total of
six tumours had inconclusive results. Five tumours were inconclusive for one protein;
one MLHI and four MSH6 with the other proteins expressed. One tumour was
inconclusive for two proteins; MLHI and MSH6 while expressing MSH2.
3.4 Family History Risk Classification and Molecular Study Correlation
Family history risk classification was completed for one hundred forty-three
families (one hundred forty-seven probands) and there is molecular tumour data, both
microsatellite and immunohistochemistry analyses, for one hundred thirty-eight families
(141 probands). As previously indicated the proband with known FAP was not family
history risk classified and therefore was not included in this portion of the results.
Tumours with MSI or inconclusive mc staining are highlighted throughout the tables.
Eight probands required special consideration in this analysis as they represented
only four families but each proband had a tumour collected and molecular analysis
completed. As all eight tumours were MSS and expressed all three proteins only one
tumour representing each family was included for a total of one hundred thirty-nine
3.4.1 High Risk Families
Seventeen (94.4%) family classified high risk families had molecular data to be
compared (Figure 4 and Figure 5). Families were classified as possible LS, FCCTX, or
age modified FCCTX according to IHC results. As previously noted, without
demonstrating a deleterious variant in a MMR gene LS cannot be definitively diagnosed
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Figure 4: Summary of Classification of High Risk Families According to Molecular
Data Results. Families classified as high risk by family history were further classified
according to lHC results. Families were classified as possible Lynch syndrome if there
was a loss of protein expression and FCCTX/age-modified FCCTX if all proteins were
expressed.
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·Onetumourhadincompletemicrosatelliteinstabilitydata
Figure 5: Molecular Data Correlation According to Specific High Risk Category.
Families initially received risk classification according to family history. High risk
families fulfilled either ACI criteria or ACMAC. Molecular analysis of tumour protein
expression further classified these families as possible LS (loss of protein expression) or
FCCTX (no loss of protein expression). Particular protein expression is highlighted
according to family classification.
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but also cannot be excluded. While IHC is not a surrogate for determining LS it does
raise clinical suspicion for a hereditary syndrome. Six (35%) families were diagnosed
with possible LS and demonstrated MSI. One family fulfilled the ACI criteria and had
loss of expression ofMSH2. The remaining five families fulfilled ACMAC and were
deficient for MLH1.
Three (18%) families were classified as FCCTX while seven (41 %) were age
modified FCCTX. Eight of these families expressed all proteins while two had
inconclusive results. Seven families were MSS with one tumour having incomplete
microsatelliteresults.
One tumour from a patient classified as ACMAC could not be collected and was
not included in the combined analysis.
3.4.2 Intermediate Risk Families
Forty-seven cases (97.9%) of those classified as IR had molecular data available
(Figure 6 and Figure 7). Forty-six had complete microsatellite and
immunohistochemistry results with one family fulfilling Bethesda criterion 5 missing
microsatellite data. Ten families fulfilling Bethesda criterion I were all MSS with
positive expression of all proteins. Of the six Bethesda criterion 2 families, five were
MSS and positive for all proteins, and one was MSI with loss of expression of MLH1.
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Figure 6: Molecular Data Correlation of MSI and IHC for Family History Classified
Intermediate Risk Families
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NOTE: Unless otherwise specified, tumours demonstrated positive expression for all proteins
Figure 7: Molecular Data Correlation ofMSI and IHC for Family History Classified
Intermediate Risk Families According to Individual Revised Bethesda Guidelines.
Intennediate risk families fulfilling more than one Bethesda criteria were classified
according to the criteria most suggestive of a Mendelian inheritance pattern. Molecular
data results were then correlated with each specific guideline.
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Two of the three families meeting Bethesda criterion 4 were MSS with one expressing
all proteins and one inconclusive for MSH6. The third family was MSI and positive for
all proteins. Twenty-seven of the twenty-eight Bethesda criterion 5 families had
complete data with twenty-five demonstrating MSS and expression of all proteins. Two
families were MSI with one expressing all proteins and one with loss of expression of
MLH1. The one family with incomplete microsatellite data expressed all proteins.
3.4.3 Low Risk Families
Seventy-four low risk families had complete molecular data available with one
tumour unable to be collected (Figure 8).
A total of forty-five informative families were MSS of which forty-three were
positive for all proteins and two had inconclusive results for MSH6. Four families were
MSI with three having loss of expression of MLH1 and one with a loss of MSH6 and
MSH2.
Twenty-five non-informative low risk families had molecular data available.
Twenty-four were MSS with twenty-three expressing all proteins and one inconclusive
for expression of MLH1. One family was MSI with loss of expression ofMLH1.
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Figure 8: Family History and Molecular Data Correlation ofMSI and IHC for
Family History Classified Low Risk Families
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3.5 Phenotype Considerations
First and second degree relatives of families classified as possible LS or FCCTX
were compared according to age of onset and frequency of CRC and ACII cancers.
Kaplan Meier survival analysis was used to illustrate any differences in age of onset.
There were a total of seventy-eight family members representing possible LS and one
hundred fifty-five for FCCTX.
3.5.1 Colorectal Cancer
Possible LS families had a mean age of CRC onset of fifty-six years of age. The
minimum age was twenty-three and the maximum eighty-six. The frequency of
occurrence was 24%. FCCTX families had a mean age of CRC onset of sixty-two years
of age with a minimum age of thirty-eight and maximum of eighty-nine years. Frequency
of CRe was 17% (Table 13). Figure 9 illustrates the later age of onset of CRC in FCCTX
families compared to possible LS which was not statistically significant (Mantel-Cox
p=O.202, Breslow p=O.IOI).
3.5.2 Extra-Colonic Cancers
As outlined in section 1.2, extra-colonic cancers are a well-defmed component of
LS. Comparison of family members with cancers as defined by the RBG including
colorectal, endometrial, stomach, ovarian, pancreas, ureter, renal pelvis, biliary tract,
brain-glioblastoma, small intestine, sebaceous gland adenomas and keratocanthomas was
completed. Possible LS families had a minimum age of onset of these extra-colonic
cancers of twenty-one years and maximum age of eighty-six years. The average age
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Table 13: Comparison of Age of Onset of CRC Occurrence between possible LS
and FCCTX Families. Minimum and maximum ages as well as mean age of CRC
onset for possible LS and FCCTX family members were compared. Frequency was
calculated based on total family members reported by family history.
Min. Age Max Age Mean Age Frequency
FAMILY
Possible LS
FCCTX
23
38
86
89
56
62
19/78=24%
27/155=17%
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Age of Diagnosis or Age of Last Follow Up
Figure 9: Comparison of Age of Onset of CRC Occurrence between possible LS and
FCCTX Families. Kaplan Meier survival curve demonstrates the later age of onset of
CRC in FCCTX families compared to possible LS. Age of onset was used for those with
a diagnosis of CRC and age of last follow up was used for those without occurrence.
(Mantel-Cox p=O.202, Breslow p=O.IOI).
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of onset was fifty-four years. The frequency of these cancers was 35%. This is compared
to the FCCTX families that had a minimum age of onset of thirty-eight and maximum age
of eighty-nine years old. Twenty three percent of FCCTX family members developed LS
associated extra-colonic cancers (Table 14). The Kaplan Meier curve in Figure 10
illustrates the earlier age of onset of these cancers in possible LS families compared to
FCCTX (Mantel-Cox p=O.069, Breslow p=O.08).
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Table 14: Comparison of Age of Onset of Extra-Colonic Cancer Occurrence
between possible LS and FCCTX Families. Minimum and maximum ages as well
as mean age of LS associated extra-colonic cancer onset for possible LS and FCCTX
family members were compared. Frequency was calculated based on total family
members reported by family history.
FAMILY
Possible LS
FCCTX
Min. Age
21
38
Max Age
86
89
Mean Age
54
63
Frequency
27/78=35%
36/155=23%
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Figure 10: Comparison of Age of Onset of Extra-Colonic Cancer Occurrence
between possible LS and FCCTX Families. Kaplan Meier survival curve demonstrates
the later age of onset of associated extra-colonic cancers in FCCTX families compared to
possible LS. Age of onset was used for those with a diagnosis of an LS associated extra-
colonic cancer and age of last follow up was used for those without occurrence.
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Chapter 4: Discussion and Conclusion
As previously noted, this study was designed to only utilizefamity history and tumour
molecular analyses, not the mutation analysis that was being completedfor the entire
CRC-IHRT study. As information regarding this analysis has since been published
reference to those results are included where applicable.
The incidence of CRC with high or intennediate family history risk is high in
Newfoundland and Labrador. 12.5% ofprobands had a family history consistent with
autosomal dominant disease, such that pedigrees show a fifty percent risk that each child
of a carrier will inherit the relevant variant and have a high risk of developing colorectal
or other associated extra-colonic cancers. Possible LS was diagnosed in a minority of
these families, and FCCTX/age modified FCCTX in the majority. Phenotype differences
exist between FCCTX and possible LS families in both age of onset, type of cancer, and
cancer frequency.
The high rate of familial CRC in NL is readily evident given that greater than
forty-five percent offamilies fulfilled high or intennediate family history risk criteria. Of
these, 12.5% were classified as ACl families while there were no ACn families. This is
more than double the percentage cited by other population-based studies which have
reported incidences between 0.3-5.8% (Aaltonen et aI., 1994; Kee & Collins, 1991;
Mecklin et aI., 1995; Ponz de Leon, 1993; Westlake et aI., 1991). While there were no
families that met ACll, there were a large proportion of families (77.8%) that displayed
multiple members across several generations with CRC and related tumours but failed to
meet the age restriction as defined by the Amsterdam criteria. Consequently, another
classification known as ACMAC was developed to further delineate this group. Families
-----------I( 80 )J---------
who failed to meet the ACII classification based on age alone were captured by adjusting
the age of diagnosis from 50 to 60 and including cancers defined by the RBG. The
Amsterdam criteria have been criticized for the stringent age restriction and this study
provides evidence for the value of this new classification. By increasing the age limit to
60, more high risk families were identified. Consequently, by clinically identifying more
high risk families earlier screening and treatment protocols can be implemented for a
larger number of at risk individuals that would otherwise have been missed. This high
percentage of familial CRC does not seem to be attributable to recruitment bias. No
significant differences between participants and non-participants were found when sex,
mean age of diagnosis, CRC tumour site, and distribution of residence were compared.
Unfortunately, only 40% of cancers affecting family history risk classification were able
to be verified. One could therefore argue a falsely elevated Amsterdam classification
secondary to inaccurately reported family cancers. However, supporting literature
demonstrates a high level of accuracy in self-reported cancers and should not be
discounted (Love et aI., 1985; Kerber et aI., 1998; Sijmons et aI., 2000).
Six (35%) high risk families were considered possible LS. Suspected diagnosis
was based on the combination of molecular tumour results and high risk family history
classification of the proband (family member) included in this study. Specifically,
probands classified as high risk and whose tumours demonstrated MSI and MMR protein
deficiency. Since the molecular elucidation ofLS, the main component for hereditary
classification has focussed on the presence ofMMR deficiency. More specifically, it has
been defmed by familial clustering of colon cancer along with evidence ofMMR protein
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deficiency with MLH1 and MSH2 accounting for 80-90% of MMR mutations in LS
(Boland, 2005). Of these six possible LS families, one had deficiency in MSH2 while the
other five lost expression ofMLHI. Interestingly, only one family fulfilled the
traditional ACI and lost expression of MSH2, while the other five were family classified
as ACMAC and lost expression ofMLHl. As reviewed in section 1.6.1, MMRdeficiency
is not an exclusive characteristic ofLS tumours. 15-20% of sporadic CRC tumours
demonstrate MSI and MLHI deficiency due to hypermethylation of the MLHI promoter
region (Poulogiannis et aI., 2010). Consequently, once LS is clinically suspected, it is
recommended to carry out germline testing of DNA MMR genes for definitive diagnosis
(Vasen et aI., 2007; Julie et aI., 2008; Jang et aI., 2010). Woods et al. (2010) tested all
tumours for MLHI promoter methylation as well as completing DNA sequencing for
tumours that were MMR deficient but lacked MLH1 promoter methylation. For the 1999
cohort discussed in this study, the only deleterious variant reported was for the ACI
family which demonstrated MSH2 deficiency. Consequently, while MLHI
hypermethylation could explain the MLHI deficiency in the remaining five ACMAC
families, the possibility of germline variants cannot be excluded. While not common,
these ACMAC families could exhibit germline methylation which has been reported in
the literature in individuals meeting clinical criteria for LS (Suter et aI., 2004; Hitchins et
aI., 2005). Secondly, of the forty-five reported MLHldeficient tumours by Woods et al.
(2010), eight had no evidence of methylation, no mutation could be found, and they were
not able to determine the occurrence of MLHI epimutations to account for the results.
While the diagnosis of LS cannot be confirmed, the family characteristics of these five
ACMAC MLH1 deficient families still exhibit significant clustering of CRC and LS
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associated extra-colonic cancers. So while they may not have an identifiable hereditary
syndrome, they still demonstrate an autosomal dominant inheritance pattern suggesting
the possibility of another familial type of CRC.
Interestingly, MMR deficiency was found in an additional seven families that
were not family history classified as high risk; two were classified as IR while five were
low risk and require further discussion.
Of the two IR families, one fulfilled the revised Bethesda criterion 2, the other
criterion 5 but both were deficient in MLH1. Using clinical and pathological criteria, the
RBG were established to capture a high proportion of LS patients by selecting tumours
that should be tested for the presence ofMSI. While not diagnostic, MSI is strongly
associated with LS as it is usually a phenotypic marker of MMR deficiency, however, for
tumours deficient in MLHl it does not identify those that are due to hypermethylation
(Boland, 2007; Poulogiannis et aI., 2010). Woods et al. (2010) reported four mutations
for families fulfilling RBG, none of which were MLH, which was the protein deficient in
my families. As described by Boland & Goel (2010), these families also exhibit the
characteristic features of sporadic CRC with MSI including the lack of significant familial
clustering and absence of the MLHl protein. Consequently, it is highly probable the
MMR deficiency demonstrated by these two families is secondary to MLHl
hypermethylation. Interestingly, while 33% of my 1999 cohort was family classified as
IR based on the RBG only 8.5% demonstrated MSl and 4.25% had MMR deficiency.
This low specificity ofRBG is consistent with other studies lending further support they
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may not be as useful as expected for identifying patients whose tumours should undergo
molecular testing (Trano et al. 2010; Terdiman et al. 2001; Syngal et al. 2000).
The five low risk families with MMR deficiency included four informative
families and one non-informative. In other words, the majority of these low risk families
had adequate size pedigrees to demonstrate familial clustering but failed to do which
decreases clinical suspicion of a hereditary syndrome. The one family classified as non-
informative was deficient in MLHI and had a pedigree of four individuals with only two
generations represented. The proband was diagnosed at age 52 and a second colorectal
cancer was reported in a parent at age 71 years. A pedigree must have six or more family
members in two successive generations potentiaIly at 50% risk of inheriting LS surviving
until at least age 60 to be considered informative. With only four family members, this
family does not meet that definition and has inadequate family history to fulfill any of the
clinical criteria despite demonstrating CRC in 50% of the pedigree in successive
generations. While this history appears to be suspicious for a hereditary syndrome,
confidence in the correct family history low risk classification increases after review of
the mutation analysis reported by Woods et al. (2010). Only one germline variant in
MSH6 was reported for low risk families which was not the study number of the proband
in this study. As the same criteria for family history low risk classification was used in
both studies, this family should also be represented in the low risk families reported by
Woods et al. and therefore correct low risk classification for this family is assumed.
The remaining four low risk informative families included three with MMR
deficiency in MLHI and one deficient in MSH2 and MSH6. The three families with
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deficiency in MLH1 had CRC diagnosed in the included proband between the ages of 62
and 72. Only one family had another colorectal cancer diagnosed at age 69 and none had
other ACn or RBG associated cancers diagnosed. Neither of these families were reported
to have specific MMR gene mutations and therefore contribute their loss of MLHldue to
hyperrnethylation of the promoter region (Woods et al. 2010). As evidenced in these
three families, the characteristic features of sporadic CRC with MMR deficiency, as
reported in the literature, include the absence of significant familial clustering, absence of
MLHl and PSM2 proteins, and the acquired silencing is usually found in older patients
(Boland & Goel 2010; Gryfe, 2006).
The final low risk family, deficient in MSH6 and MSH2, had a family pedigree
consisting of fourteen family members dispersed over three generations with the proband
diagnosed at age fifty. Only three incidences of cancer were reported: pathologically
confinned cancer of the cervix in a sibling diagnosed at age 47, as well as breast and liver
cancer in two second degree relatives at unknown ages of diagnosis. Molecularly, this
family lost the MSH21MSH6 MMR complex and had corresponding MSI suggesting LS,
but the familial cancers were not LS associated extra-colonic cancers. Interestingly,
Woods et al. (2010) reported this family to have a novel gene mutation in MSH6 and
therefore, while unexpectedly, are confinned to have LS. While discrepancies between
molecular analyses and family history have been well documented it is probable the
phenotypic expression seen in this family may be unique to this specific deleterious
variant. Alternatively, it may be the result of environmental effects or other genetic
factors within this family.
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For the total population studied LS incidence was 2.1 %. Of one hundred forty
four families, three had confirmed germline variants; 2 MSH2 and I MSH6 (Woods et aL,
2010). Comparatively, Woods et aL (2010) report a total proportion of2.7% MMR
mutations from a total of 750 patients. This estimate, however, is likely conservative as
there were an additional fifteen tumours with MMR deficiency and no identifiable cause.
Newfoundland and Labrador demonstrates a similar frequency of possible LS compared
to other populations that estimate incidence between 0.9-2.7% (Salovaara et al., 2000;
Aaltonen et al., 1998; Cunningham et al., 2001; Ravnik-Glevac et al., 2000; Percesepe et
al., 2001; Samowitz et al., 2001; Goodfellow et al., 2001). However, the incidence from
our population is likely higher when you include the families with probable novel
germline mutations.
There were some inconsistencies between MSI and MMR protein deficiency.
MSI is the accepted phenotype of MMR deficiency and although correlation between the
two molecular analyses is expected it is not uncommon to fmd otherwise (Rovella, 2001).
Fifteen (10.9%) families demonstrated MSI with only thirteen (86.7%) having a
corresponding deficiency in MMR proteins. These two discrepant tumours were from
probands who were family history classified as IR; one according to Bethesda criterion-4
and the other criterion-5. The family fulfilling criterion 4 reported ovarian cancer in the
proband's sibling at age 35 (permission was declined to review medical records and was
unable to be confirmed) and CRC was diagnosed in the proband at age 72. Ovarian
cancer is an associated LS extra-colonic cancer and with diagnosis less than age 50 the
likelihood of a hereditary component increases. The second family, which fulfilled
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Bethesda criterion 5, reported three incidences of cancer: stomach cancer in the proband's
parent (pathologically confirmed age 65) and grandparent (age unknown), and lung
cancer in the proband's sibling at age 47 (pathologically confirmed). This family has
documented ACII cancers in three generations but unfortunately does meet the age
criteria for ACII diagnosis. With clear evidence of family history and demonstrated MSI
these families are higWy suspicious of LS and would be expected to have MMR
deficiency. There are several explanations that may account for this. Firstly, this study
did not include all known associated MMR genes. Secondly, molecular techniques
including discordance between MSI and IHC panels in addition to poor tumour fixation
may be responsible (Shia J et al. 2004). Thirdly, research has demonstrated a percentage
of LS tumours that do not exhibit any detectable MMR protein expression abnormality
despite demonstrating MSI (Poulogiannis et aI., 2010; Hampel et aI., 2008; Pinol et aI.,
1986). Finally, a yet to be identified MMR protein that is involved in development of LS
may be responsible. Woods et al. (2010) did not report any germline variant for these
families and also cited discordance between IHC, MS1, and mutation status.
The majority offamily history classified high risk families (65%) were
categorized as FCCTX/age modified FCCTX. Specifically, families who fulfilled ACI
and ACMAC but did not demonstrate tumour molecular evidence of LS including MSI or
MMR deficiency were categorised as FCCTX and age-modified FCCTX respectively.
FCCTX was found in 17.6% and age modified FCCTX in a further 47.1 %. Results of
mutation analysis for FCCTX families reported by Woods et al. (2010) (they did not
include the age modified FCCTX family classification) did not identify any deleterious
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variants in the genes extensively studied and there was no evidence of methylator
pathway dysfunction for these families. Of note however, three tumours from age-
modified FCCTX had inconclusive MMR results. All three were microsatellite stable but
had inconclusive staining for MSH6 which is known to lack the usual phenotypical
staining. Specifically, despite having a deleterious variant, MSH6 is able to preserve
some DNA MMR and typical MSI may not be observed and will demonstrate MSS
(Kolodner et aI., 1999). These ambiguities could be related to poor technique or possibly
changes were too subtle to be detected by the usual methods. However, with such a high
frequency of these families identified, the more likely explanation is the possibility of
novel deleterious variants in this population.
The phenotype of FCCTX (including age-modified FCCTX) families differed
from those classified as possible Lynch. FCCTX families had a lower frequency ofboth
CRC and LS associated extra-colonic cancers as well as a later age of cancer onset
compared to probable LS family members. With a larger sample size, results from
Woods et al. confirmed the age at CRC diagnosis of patients categorised as FCCTX was
significantly higher than LS patients, p<O.OII, however they did not examine the tumour
spectrum between FCCTX and LS families. While the higher incidence of cancers for
either group may be due to the larger family sizes found in NL and thereby increasing the
chance of finding more cancers, these findings are consistent with that found in other
studies (Rovella et aI., 2000; Park et aI., 2007; Perea et aI., 2010). Although the results of
my cohort were not statistically significant, they may be clinically significant. Insights
into phenotypic expression clinically impacts patient management such as necessary
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screening protocols for affected family members. Phenotypes are dependent on the
underlying genetic background of the mutations in the population studied making direct
comparison to other studies difficult. While these observations may suggest a similar
phenotypic expression, further information about the particular mutation and genotype-
phenotype mechanism is necessary.
There are multiple limitations of this study that must be considered. This study
was only one year in duration with a small sample size of 148 participants representing
144 families. Comparative studies have been years in duration with hundreds of
participants. A longer study interval, such as the CRC-IHRT which has been recently
completed with a total of 750 patients, provides a more reliable data set and reduces the
possibility of chance aggregation. Secondly, this was a cross-sectional study with
retrospective assessment and verification of reported cancers. If recruitment at diagnosis
had been possible it is conceivable that a greater number of relative cancers and tumour
samples would have been obtained. Thirdly, this study did not include all known
associated MMR proteins. This may explain the discordance between MSI and MMR
protein deficiency. MLHl and MSH2 are the most common proteins affected, however,
PMSl and PMS2, albeit to a lesser extent, have also been identified (de la Chapelle,
2004). Additionally, the contribution ofMLHl hypermethylation was not determined.
Up to 10-12% of all CRCs which show MSI develop instability due to this acquired
defect while only 3-4% is due to LS (Boland et al. 2008). Consequently, the absolute
proportion ofLS families is unable to be determined and only a suspected percentage is
possible. Further molecular analysis is needed to appropriately classify the tumours with
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MLH1 deficiency. The effect of environment and lifestyle on cancer development was
also not evaluated. An analysis comparing lifestyle factors between possible Lynch and
FCCTX families would eliminate this possible confounding variable. Finally, this study
did not include DNA mutation testing which is an integral part to understanding these
genetic syndromes and cannot be overlooked. While this information is now available
and referenced where possible, it was not designed to be part of this study.
Despite these limitations, this study has some important implications. The high
number of clinically diagnosed FCCTX families as well as LS in this population (using
mutation results published by Woods et al. (2010) demonstrates the need for appropriate
screening in the whole population. There are likely many families yet to be identified and
population based screening should be considered. The high frequency of families
classified as FCCTX suggests the possibility of other pathways in the development of
CRC in the Newfoundland population. There could be more involvement of deleterious
variants in oncogenes or tumour suppressor genes as opposed to the traditional mutator
pathway. Given the basis of the NL founder population there exists the possibility of
novel genes. Finally, the variations in phenotype are important when counselling and
screening affected families. As FCCTX families do not appear to follow the typical LS
phenotype one cannot follow the prototypical screening guidelines. Screening may need
to be tailored according to one's family and the trends illustrated in this study suggesting
less extensive and later onset screening. Further in-depth genetic research is needed in
this population to further characterize the mutations and the genotype-phenotype
mechanism(s) in these high risk families. Consequently, while the scientific relevance of
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this study may be questioned due the lack of mutation analysis results, its clinical
relevance cannot be overlooked.
In conclusion, the aim of this study was to determine the genetic basis of
colorectal cancer in NL, defined by family history and molecular pathology of the CRC in
an incident cohort ofCRC cases occurring in the population aged 20-74 during one year.
Incidence ofCRC with high or intermediate family history risk is high in NL. Families
with a history consistent with autosomal dominant disease occurred in 12.5%; LS was
presumed in a minority of these families, and FCCTXlage modified FCCTX in the
majority. FCCTX families are characterized by later onset colorectal and LS associated
extra-colonic cancers, as well as lower family occurrence of these cancers. This study
was part ofa larger, collaborative project that completed a more in-depth analysis of the
hereditary cancer syndromes demonstrated here. Further information on genotype,
phenotype and underlying genetic process will allow physicians to better identify high
risk individuals at an earlier age and provide them and their families with the appropriate
screening and treatment modalities. This will help to decrease the morbidity and
mortality associated with these genetic syndromes. Finally, the opportunity for novel
gene discovery exists as the molecular genetic basis for most of those with familial CRC
was not determined.
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